---
document_datetime: 2023-09-21 17:05:50
document_pages: 63
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/acrescent-epar-refusal-public-assessment-report_en.pdf
document_name: acrescent-epar-refusal-public-assessment-report_en.pdf
version: success
processing_time: 52.8991351
conversion_datetime: 2025-12-18 09:00:37.38289
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

18 October 2012 EMA/111381/2013 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Acrescent

International non-proprietary name: memantine hydrochloride / donepezil hydrochloride

Procedure No. EMEA/H/C/002424

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ACh         | Acetylcholine                                                                                         |
|-------------|-------------------------------------------------------------------------------------------------------|
| AChE        | Acetylcholinesterase                                                                                  |
| AChEI       | Acetylcholinesterase inhibitor                                                                        |
| AD          | Alzheimer's disease                                                                                   |
| ADAG-cog    | Alzheimer's disease assessment scale - cognitive subscale                                             |
| ADCS-ADL    | Alzheimer's disease cooperative study - activities of daily living inventory                          |
| ADCS-CGIC   | Alzheimer's disease cooperative study - clinical global impression of change                          |
| ADDF        | Alzheimer's drug discovery foundation                                                                 |
| ADL         | Activities of daily living inventory                                                                  |
| ADMC        | Alzheimer's Disease Management Council Clinical Consensus Panel                                       |
| ADME        | Absorption, distribution, metabolism, and excretion                                                   |
| AE          | Adverse event                                                                                         |
| ANCOVA      | Analysis of covariance                                                                                |
| APTS        | All patients treated set                                                                              |
| ARW-DSP     | Adelphi Real World Disease Specific Programme                                                         |
| ASHA-FACS   | American speech-language-hearing association functional assessment of communication skills for adults |
| AUC (0-24h) | Area under the plasma concentration-time curve from zero to 24 hours post-dose                        |
| AUC(I)      | Area under the %inhibition-time curve                                                                 |
| BALDS       | Bristol Activities of Daily Living Scale                                                              |
| BBSI        | Brain boundary shift integral                                                                         |
| BCS         | Biopharmaceutics classification system                                                                |
| BDS         | Blessed Dementia Scale                                                                                |
| BGP         | behavioral rating scale for geriatric patients                                                        |
| BMI         | body mass index                                                                                       |
| CCI-OT      | Cegedim Customer Information Online Tracker                                                           |
| CGI-I       | Clinical global impression - global improvement                                                       |
| CGI-S       | Clinical global impression - severity of illness                                                      |
| CI          | Confidence interval                                                                                   |
| CIBIC       | Clinician's interview-based impression of change                                                      |
| Cl/F        | Oral clearance; defined as dose/AUC0-inf                                                              |
| Cltot       | Clearance total                                                                                       |
| CMAI        | Cohen mansfield agitation inventory                                                                   |
| Cmax        | Maximum plasma concentration                                                                          |
| CSD-LPD     | Cegedim strategic data- longitudinal patient databases                                                |
| CSF         | Cerebro spinal fluid                                                                                  |
| CT          | Computerised tomography                                                                               |
| DE          | Germany                                                                                               |
| EFNS        | European Federation of Neurological Societies Environmental risk assessment                           |
| ERA         |                                                                                                       |
| ER          | Extended release formulation                                                                          |
| ES          | Spain                                                                                                 |
| EU          | European Union                                                                                        |
| FAS         | Full analysis set Functional assessment                                                               |
| FAST        | staging                                                                                               |
| FDC         | Fixed dose combination                                                                                |
| FLCI        | Functional linguistic communication inventory                                                         |
| Fpen        | Fraction of a population receiving the drug substance during a given time                             |
| FR          | France                                                                                                |
|             | Good clinical practices                                                                               |
| GCP GLP     | Good laboratory practices                                                                             |
| GP          | General Practitioner                                                                                  |
|             | hachinski ischaemia scale                                                                             |
| HIS HSQ-12  | health status questionnaire                                                                           |
| IC Imax     | Half maximum inhibitory concentration Maximum percentage of                                           |
|             | inhibition                                                                                            |

<div style=\"page-break-after: always\"></div>

| IMP          | Investigational medicinal product                                                                                                 |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------|
| IMS-IPD      | IMS-Prescribing Insights Database                                                                                                 |
| ip           | intraperitoneal                                                                                                                   |
| IT           | Italy                                                                                                                             |
| ITT          | Intent to treat                                                                                                                   |
| LC/MS/MS     | Liquid chromatography with tandem mass spectrometric detection                                                                    |
| LOCF         | Last observation carried forward                                                                                                  |
| Log Kow      | octanol-water partition coefficient                                                                                               |
| MADRS        | Montgomery and åsberg depression rating scale                                                                                     |
| MCID         | Minimal clinically important difference                                                                                           |
| MDS          | Minimum data set                                                                                                                  |
| MEM/DPZ      | Memantine/ donepezil                                                                                                              |
| MMSE         | Mini mental state examination                                                                                                     |
| MoA          | Mechanism of Action                                                                                                               |
| MOSES        | Multidimensional Observation Scale for Elderly Subjects                                                                           |
| MRI          | Magnetic resonance imaging                                                                                                        |
| NICE         | National institute for health and clinical excellence                                                                             |
| NINCDS-ADRDA | National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association |
| NMDA         | N-methyl-D-aspartate                                                                                                              |
| NOAEL        | No observed adverse effect level                                                                                                  |
| NPI          | Neuropsychiatric inventory                                                                                                        |
| NPI-NH       | Neuropsychiatric inventory- nursing home                                                                                          |
| OC           | Observed Case                                                                                                                     |
| PANSS-EC     | positive and negative syndrome scale - excited component                                                                          |
| PBO/DPZ      | Placebo/ donepezil                                                                                                                |
| PECsw        | Estimation of exposure of surface water (for calculation)                                                                         |
| pKa          | Acid dissociation constant                                                                                                        |
| RBC          | Red blood cell                                                                                                                    |
| RUD          | Resource utilization in dementia                                                                                                  |
| SAE          | Serious adverse event                                                                                                             |
| SIB          | Severe impairment battery                                                                                                         |
| SMMSE        | Standardised mini-mental state examination                                                                                        |
| TBV          | Total brain volume                                                                                                                |
| TK           | Toxicokinetic                                                                                                                     |
| Tmax         | Time to maximum observed concentration                                                                                            |
| UK           | United kingdom                                                                                                                    |
| US           | United states                                                                                                                     |
| Vz/F         | Apparent volume of distribution; calculated as cl/f/λz                                                                            |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................5                                 |                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................         | 5                                                                                                                    |
| Information on Paediatric requirements .......................................................................             | 5                                                                                                                    |
| Information relating to orphan market exclusivity..........................................................                | 5                                                                                                                    |
| Scientific Advice                                                                                                          | ....................................................................................................... 5            |
| Licensing status                                                                                                           | ....................................................................................................... 5            |
| 1.2. Steps taken for the assessment of the product .......................................................                 | 5                                                                                                                    |
| 2. Scientific discussion ................................................................................7                 |                                                                                                                      |
| 2.1. Introduction ......................................................................................................   | 7                                                                                                                    |
| 2.2. Quality aspects ..................................................................................................    | 7                                                                                                                    |
| Manufacture                                                                                                                | ............................................................................................................ 8       |
| Specification                                                                                                              | ............................................................................................................ 8       |
| Stability                                                                                                                  | .................................................................................................................. 8 |
| Manufacture                                                                                                                | ............................................................................................................ 9       |
| Specification ............................................................................................................ | 9                                                                                                                    |
| Stability                                                                                                                  | ................................................................................................................ 10  |
| Pharmaceutical Development ...................................................................................             | 10                                                                                                                   |
| Adventitious agents ................................................................................................       | 11                                                                                                                   |
| Manufacture of the product ......................................................................................          | 11                                                                                                                   |
| Product specification ...............................................................................................      | 11                                                                                                                   |
| Stability of the product............................................................................................       | 11                                                                                                                   |
| 2.3. Non-clinical aspects..........................................................................................        | 12                                                                                                                   |
| 2.4. Clinical aspects ................................................................................................     | 17                                                                                                                   |
| GCP......................................................................................................................  | 18                                                                                                                   |
| 2.5. Clinical efficacy ................................................................................................    | 27                                                                                                                   |
| 2.6. Clinical safety ..................................................................................................    | 52                                                                                                                   |
| 2.7. Pharmacovigilance............................................................................................         | 59                                                                                                                   |
| 2.8. User consultation .............................................................................................       | 59                                                                                                                   |
| 3. Benefit-Risk Balance............................................................................60                      |                                                                                                                      |
| Benefits ................................................................................................................  | 60                                                                                                                   |
| Risks .................................................................................................................... | 61                                                                                                                   |
| Benefit-risk balance ................................................................................................      | 62                                                                                                                   |

4.

Recommendations ...............................................................................  63

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant H. Lundbeck A/S submitted on 1 June 2011  an application for Marketing Authorisation to the European Medicines Agency (EMA) for Acrescent, through the centralised procedure under Article 3(2)(b) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by  the  EMA/CHMP  on  28  September  2010.  The  eligibility  to  the  centralised  procedure  under  Article 3(2)(b)  of  Regulation  (EC)  No  726/2004  was  based  on  demonstration  of  interest  of  patients  at Community level.

The applicant applied for the following indication: treatment of patients with moderate to moderately severe Alzheimer's disease who are already on a stable daily dose of 20 mg memantine and 10 mg donepezil.

## The legal basis for this application refers to:

Article 10(b) of Directive 2001/83/EC - new fixed combination application.

The application submitted is a new fixed combination medicinal product.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/345/2010 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000,  the  applicant  did  not  submit  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific Advice

The applicant did not seek scientific advice at the CHMP.

## Licensing status

The product was not licensed in any country at the time of submission of the application.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Concepcion Prieto Yerro

Co-Rapporteur:

Bruno Sepodes

<div style=\"page-break-after: always\"></div>

- The application was received by the EMA on 1 June 2011.
- The procedure started on 22 June 2011. The Rapporteur's first Assessment Report was circulated to all CHMP members on 14 September 2011. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 14 September 2011.
- During the meeting on 20 October 2011, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 26 October 2011.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 22 March 2012.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 7 May 2012.
- During the CHMP meeting on 24 May 2012, the CHMP agreed on a list of outstanding issues to be addressed in writing and in an oral explanation by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 15 August 2012.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues on 3 September 2012.
- During the CHMP meeting on 18 September 2012, outstanding issues were addressed by the applicant during an oral explanation before the CHMP.

During the meeting on 18 October 2012, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

This is a fixed combination application, Article 10(b) application for Acrescent (Memantine/Donepezil) for  known  active  substances  through  the  centralised  procedure.  The  fixed  combination  product  is intended for prescription only.

Memantine  is  a  voltage-dependent,  moderate-affinity,  uncompetitive  N-methyl-D-aspartate  (NMDA) receptor antagonist. It is claimed as a modulator of the effects of pathologically elevated tonic levels of glutamate  that  may  lead  to  neuronal  dysfunction  and  has  been  authorised  via  the  centralised procedure for the treatment of patients with moderate to severe Alzheimer's disease (AD).

Donepezil is a selective, reversible acetylcholine esterase inhibitor (AChEI), the predominant cholinesterase  in  the  brain.  Donepezil  has  been  authorised  via  the  mutual  recognition  procedure  in several  Member  States  for  the  symptomatic  treatment  of  patients  with  mild  to  moderately  severe Alzheimer´s dementia.

AD  is  a  slowly  progressive  disease  of  the  brain  that  is  characterized  by  impairment  of  patient's cognition and eventually by disturbances in reasoning, planning, language, and perception.  AD results from  an  increase  in  the  production  or  accumulation  of  beta-amyloid  protein  and  degeneration  of neurons.  As  the  disease  progresses,  the  neurodegeneration  spreads  and  affects  also  serotonergic, noradrenergic, and glutamatergic neurons. The incidence of Alzheimer's disease is approximately 10% in the population over 65 years of age and increases progressively with age to reach about 30% by the end of a century of life. Currently, available pharmacological therapies are the AChEI (e.g donepezil, galantamine  and  rivastigmine)  and  memantine  that  are  acting  on  AD  with  different  mechanisms  of action (MoA) as explained above.

Acrescent is a fixed-dose combination (FDC) product of memantine (20 mg) and donepezil (10 mg), presented as film-coated tablets (memantine 20 mg/donepezil 10 mg). Acrescent has been developed as  a  substitution  indication  i.e.  in  patients  adequately  controlled  with  the  individual  products  given concurrently at the same dose level as in the combination, but as separate tablets. This simplification of therapy by decreasing the number of individual dose units to be taken by the patient may improve patient compliance and was therefore considered as a potential therapeutic advantage to support the present application.

The claimed indication is: treatment of adult patients with moderate to moderately severe AD who are already on a stable daily dose of 20 mg memantine and 10 mg donepezil. The recommended dose is one tablet per day.

## 2.2. Quality aspects

## 2.2.1. Introduction

Acrescent is a fixed dose combination product of two well-known stable active substances, memantine hydrochloride  and  donepezil  hydrochloride.  It  is  presented  as  film-coated  tablets  containing  20  mg memantine/10 mg donepezil in alu/alu blisters.

The full list of ingredients is defined in section 6.1 of the SmPC.

<div style=\"page-break-after: always\"></div>

## 2.2.2. Active Substance

## Memantine hydrochloride

Memantine chemical name (IUPAC) is 3,5-dimethyladamantan-1-amine hydrochloride . It appears as is a white, almost odourless crystalline powder, highly soluble in water. Its pKa-value is 10.3 and shows a partition coefficient of log P = 3.28. The active substance has two chiral centres but since there is a plane of symmetry between them, the molecule is not chiral and it exhibits only one polymorphic form.

It  corresponds  to  the  molecular  formula  C12H21N·HCl and has a molecular mass 215.77 g/mol (as hydrochloride); 179.31 g/mol (free base).

## Manufacture

The  active  substance  memantine  hydrochloride  is  sourced  from  two  different  sources.  One  of  the suppliers  utilizes  two  different  synthetic  routes.    The  documentation  on  the  active  substance  is presented in three different Active Substance Master Files (ASMF). The synthetic steps are described in all  three  ASMF  sufficiently.  Details  regarding  the  materials,  intermediates,  process  validation  and manufacturing process development have been satisfactorily presented. The synthetic processes used by  the  proposed  manufacturers  are  very  similar.  The  starting  material  used  in  the  synthesis  of Memantine HCl is the same for the three processes. The same intermediates are obtained, but they could be isolated or not depending on the process. Moreover, there are small differences in a solvent, some reagents and reaction conditions among the processes, but these differences are of no relevance, since they are consequence of optimization of the process in the respective manufacturing facilities.

## Specification

The  specification  of  the  memantine  as  set  up  by  the  drug  product  manufacturer  includes  tests  and limits  for  appearance, colour and colour of solution (visual), odour (organoleptic), solubility (visual), identification of active substance and chloride (IR, chemical), assay of active substance and chloride (titration),  impurities  (GC  or  HPLC),  heavy  metals  (Ph.  Eur.),  residual  solvents  (GC),  loss  on  drying (Ph. Eur.), sulphated ash (Ph. Eur.) and particle size (laser diffraction). Satisfactory justification has been presented for the omission of microbiological testing in the specification of memantine. Sufficient justification on the proposed controls has been provided in accordance with the Guideline on the Limits of Genotoxic Impurities (EMEA/CHMP/QWP/251344/2006) for the potential genotoxic impurities.

The specifications are adequate to control the quality of the active substance. The impurity limits are acceptable and there is no concern from the point of view of safety.

Batch  analysis  data  is  presented  for  at  least  three  production  batches  manufactured  by  all  three processes  from  each  memantine  supplier.  All  the  results  reported  are  all  within  the  proposed specifications.

## Stability

The  stability  studies  were  carried  out  on  at  least  three  commercial  scale  batches  of  memantine hydrochloride from both suppliers manufactured by all proposed processes.

Results were presented for up to 60 months at 25ºC/60%RH and 6 months at 40ºC/75%HR according to defined stability protocols, and in accordance with the ICH guidelines on stability. Memantine was packaged in all cases in the simulate market container.

<div style=\"page-break-after: always\"></div>

The stability samples were evaluated as per defined stability protocols for appearance, water or loss on drying, assay, and impurities. Depending on the stability protocol some samples were also tested for identification, clarity of solution, colour of solution.

The test methods used during stability are those used for release. The analytical methods used have been suitably validated and are stability indicating methods.

Photostability and stress testing (acidic and alkaline hydrolytic and oxidative) of the active substance has  been  investigated  on  two  representative  batches  of  the  active  substance  and  no  significant degradation  has  been  observed  when  exposed  to  light  or  other  stress  tested  conditions  apart  from oxidative treatment with KMnO4.

The proposed re-test period and storage conditions are supported by the overall results.

## 2.2.3. Active Substance

## Donepezil hydrochloride

Donepezil chemical name chemical name (IUPAC) is 2-[(1-benzyl-4-piperidyl)methyl]- 5,6-dimethoxy2,3-dihydroinden-1-one  hydrochloride  monohydrate.  It  appears  as  is  a  white  to  off-white,  slightly hygroscopic crystalline powder, freely soluble in water, methanol and acetic acid. Its pKa-value is 9.08. It corresponds to the molecular formula C24H29NO3·HCl·H2O and has a molecular mass 433.98 g/mol (as  hydrochloride  hydrate);  379.50  g/mol  (free  base).  It  has  one  chiral  centre  and  the  active substance is a racemic mixture.

It exhibits polymorphism and exists in different polymorphic forms designated form I, II, III, IV and V. Donepezil hydrochloride synthesised by both suppliers is the same form I, based on the comparison of IR spectra and X ray powder diffraction patterns.

## Manufacture

The active substance donepezil hydrochloride is sourced from two different sources. The documentation  on  the  active  substance  Donepezil  hydrochloride  is  also  presented  as  two  separate ASMFs. The synthetic steps are described in both ASMFs sufficiently. Details regarding the materials, intermediates,  process  validation  and  manufacturing  process  development  have  been  satisfactorily presented.  The  synthetic  processes  used  by  the  proposed  manufacturers  are  very  similar.  Some differences in solvents, reagents or reaction conditions are minor and both processes yield material of comparable quality.

## Specification

The specification of donepezil as set up by the drug product manufacturer includes tests and limits for appearance  (visual),  identification  of  active  substance  and  chloride  (IR,  HPLC,  chloride:  Ph. Eur.), assay (HPLC), impurities  (HPLC),  heavy  metals  (Ph.  Eur.),  residual  solvents  (GC),  water  (Ph.  Eur.), microbiological purity (Ph. Eur.- not routinely), and sulphated ash (Ph. Eur.).

Sufficient justification on the proposed controls and limits has been provided in accordance with the Guideline  on  the  Limits  of  Genotoxic  Impurities  (EMEA/CHMP/QWP/251344/2006)  for  the  potential genotoxic impurities.

The specifications are adequate to control the quality of the active substance. The impurity limits are acceptable and there is no concern from the point of view of safety.

<div style=\"page-break-after: always\"></div>

Batch analysis data is presented for at least three production batches from each donepezil supplier. All the results reported are all within the proposed specifications.

## Stability

The stability studies results were presented on six commercial scale batches of donepezil manufactured the one supplier and on three commercial scale batches from the second

Results were presented for up to 36 months at 25ºC/60%RH and 6 months at 40ºC/75%HR according to  defined  stability  protocols,  and  in  accordance  with  the  ICH  guidelines  on  stability.  Donepezil  was packaged in both cases in the simulate market container.

The stability samples were evaluated for appearance, assay, water, related substances and identification.  The  test  methods  used  during  stability  are  those  used  for  release.  The  analytical methods  used  for  determination  of  assay  and  related  substances  have  been  suitably  validated  as stability indicating methods.

Photostability of the active substance has been investigated by both suppliers as per the relevant ICH guideline. No significant degradation has been observed when exposed to light.

Stress testing hydrolytic and oxidative conditions in solution and in powder form has been performed. The  structures  of  probable  degradation  products  in  hydrolytic  and  oxidative  conditions  have  been provided and are considered not to raise any concern.

The proposed re-test period and storage conditions are supported by the overall results.

## 2.2.4. Finished Medicinal Product

## Pharmaceutical Development

Acrescent fixed dose combination formulation was designed as film tablet to be bioequivalent to the marketed 20 mg memantine hydrochloride tablets Axura / Ebixa and 10 mg donepezil hydrochloride tablets Aricept.

Acrescent finished product is presented as pale yellow to light yellow, oval shaped film-coated tablet with imprint 'MEM' on one side and imprint 'DON' on the other side.

The  starting  point  for  the  formulation  development  activities  was  the  existing  and  successfully marketed drug products Axura / Ebixa 20 mg film coated tablet and their established and validated manufacturing process.

Both  active  ingredients,  memantine  hydrochloride  and  donepezil  hydrochloride  monohydrate,  are crystalline  powders  with  suitable  flow  properties.  The  qualitative  composition  of  the  marketed  drug product Axura / Ebixa 20 mg film coated tablet was in principle not modified apart from the addition of donepezil.

Although  it  is  known  that  crystalline  memantine  can  exist  in  two  plates  and  needles,  the  results provided by the two manufacturers showed consistently the same needle shape. Donepezil exists in various polymorphic forms but only the polymorph 1 is was used in the formulation.

Because  the  solubility  of  both  active  substances  is  very  high  and  are  classified  as  BCS  class  I compounds, their particle size is not considered critical in the manufacturing process and the product performance. Both substances are rapidly dissolved from the dosage form (within 15 min).

<div style=\"page-break-after: always\"></div>

All excipients in the formulation are standard excipients of pharmaceutical quality appropriate for their intended use and have been used in oral solid dosage forms for already long time.

The compatibility between the actives substances and excipients was demonstrated by stress studies of binary mixtures between the active substances and the excipients.

The  manufacturing  process  is  based  upon  the  manufacturing  process  approved  for  the  marketed memantine 20 mg film-coated tablets. The process parameters have been optimised with regard to the core tablets and the coating. It has been found the process is unaffected by the changes introduced. In-process control tests were identified to control the manufacturing process adequately.

The impact of the different active substance sources was investigated during development and it was found it does not affect manufacture or the finished product quality. Scaling up and the influence of the main manufacturing process operations was investigated and no critical parameters were identified.

The drug product will be packaged in aluminium/aluminium blister pack.

## Adventitious agents

The tablets do not contain excipients of human or animal origin.

## Manufacture of the product

The manufacturing process is essentially the same as the approved for Axura/ Ebixa tablets. It is a standard direct compression method for tablet manufacture comprising several blendings, compression and film coating. There are no critical steps in this manufacturing process. Data obtained during the development of the proposed product together with extensive experience in the manufacture of Axura/ Ebixa 20 mg tablets demonstrate that the manufacturing process is robust. The in-process controls are considered  suitable  and  sufficient  to  ensure  the  quality  of  the  tablets  manufactured.  There  are  no intermediates isolated during the manufacture of the tablets.

The  process  will  be  validated  on  the  first  three  consecutive  production  batches  which  is  acceptable taking  into  account  that  is  a  standard  manufacturing  process  and  the  experience  with  very  similar authorised products.

## Product specification

The  finished  product  release  and  shelf-life  specifications  includes  tests  and  limits  for  appearance (visual), identification (HPLC, UV), assay (HPLC), uniformity of mass (Ph. Eur.), uniformity of dosage units (Ph. Eur.- non routinely), degradation products (GC and HPLC), dissolution (HPLC- Ph. Eur. ) and Microbial quality (Ph. Eur.- non routinely).

Satisfactory batch data have been provided for three commercial scale batches. All parameters were within  specification.  The  reported  results  indicate  that  the  process  is  under  control,  confirming consistency and uniformity of manufacture.

## Stability of the product

The stability studies were conducted on six pilot batches of tablets at 25°C/60%RH, 30ºC/75%RH and 40°C/75%HR according to defined stability protocols, which follow the ICH guidelines on stability.

The batches were packed in the proposed packaging. Results were presented for up to 18 months at 25ºC/60%RH and 30ºC/75%RH and up to12 months at 40ºC/75%RH.

<div style=\"page-break-after: always\"></div>

Samples have been tested for appearance, uniformity of mass and average weight, dissolution, assay, purity and microbiological quality. The parameters are considered relevant and adequate to assess the stability  of  the  drug  product.  The  analytical  methods  used  for  determination  of  assay  and  related substances have been suitably validated as stability indicating methods.

A  slight  increase  of  the  content  of  some  donepezil  related  degradation  product  at  accelerated conditions  after  9  months  was  observed.  However  they  still  remain  well  within  the  shelf  life specification limits. For all other parameters tested no significant changes are observed.

Stability of bulk tablets has been studied and appropriate shelf life and storage conditions have been established

The proposed shelf-life and storage conditions are considered justified.

## 2.2.5. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substances and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in the clinic.

## 2.2.6. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC.  Physicochemical  and  biological  aspects  relevant  to  the  uniform  clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.7. Recommendation(s) for future quality development

Not applicable.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The non clinical programme considered the CHMP Guideline on the Non-Clinical Development of Fixed Medicinal Products (CPMP/SWP/258498/2005) and was limited to two non clinical studies characterising the pharmacodynamic and toxicology profiles of the use of this combination. All other submitted data were derived from the literature.

The pivotal toxicology study was performed according to Good Laboratory Practices (GLP), as stated by the applicant.

## 2.3.2. Pharmacology

A  limited  pharmacology  program  has  been  conducted  by  the  applicant  and  consisted  of  one  study specifically evaluating the effect of the combination (memantine/donepezil) on extracellular acetylcholine levels.

## 2.3.2.1. Primary pharmacodynamic studies

## Memantine

<div style=\"page-break-after: always\"></div>

Memantine is an uncompetitive NMDA receptor antagonist and was found to have a free brain exposure of  0.5-0.8  μM  at  clinical  relevant  doses  obtained  30-60  min  after  5  mg/kg  intraperitoneal  (i.p) administration in rats. Memantine also blocked NR1 co-expressed with NR2A, NR2B, NR2C or NR2D receptors  in  Xenopus  oocytes  with  IC50  of  0.89  μM,  0.40  μM,  0.32  μM  or  0.28  μM  respectively. Memantine has shown to interact with 5HT3 and nAChR receptors with IC50 values of 2.29 μM and 6.6 μM respectively. On α7 nAChR, the potency of memantine varied considerably from 0.3 μM to 6.6 μM depending  on  expression  system.  Memantine  also  exhibited  generalization  to  other  NMDA  receptor antagonists,  with  a  modest  attenuation  to  nicotine  at  10  mg/kg  i.p.  in  rats,  indicative  for  a predominant NMDA receptor block.

## Donepezil

Donepezil is a selective non-competitive piperidine-class AChE inhibitor. Donepezil showed inhibitory effects on rat brain AChE and rat plasma ButylCholinesterase (BuChE), with an IC50 of 6.7 μM and 7.4 μM, respectively. Oral administration of donepezil inhibited brain AChE in a dose-dependent manner. The estimated p.o dose of donepezil to inhibit 50% of brain AChE is 2.6 mg/kg in rats.

## 2.3.2.2. Secondary pharmacodynamic studies

No  studies  described  specifically  as  secondary  pharmacodynamic  have  been  performed  with  the combination (memantine/donepezil).

## 2.3.2.3. Safety pharmacology programme

No safety pharmacology studies have been performed with the combination (memantine/donepezil).

## 2.3.2.4. Pharmacodynamic drug interactions

The applicant specifically evaluated the effect of the combination (memantine/donepezil) on extracellular acetylcholine (ACh) levels by microdialysis in dorsal hippocampus of freely moving rats. Results showed that 5 mg/kg s.c of memantine did not produce any measurable changes in ACh while 1.3 mg/kg subcutaneous (s.c) administration of donepezil induced a 1223% ± 239% increase in ACh at the maximal effect after 80 minutes. Literature data also reported increases on brain extracellular concentration of ACh (and dopamine and noradrenalin) at high memantine doses (20 mg/kg i.p.). In the presence of neostigmine and memantine (5mg/kg), ACh level was found to be increased of 160% in the tested region (hippocampus). Additional systemic inhibition by donepezil (0.5 mg/kg) increased the ACh level by approximately 600%, in the presence of memantine (5mg/kg).

Based on literature, in vitro data suggested that there was no attenuation of the effect of donepezil inhibition on AChE in the presence of memantine at either 1 μM or 5 μM. Memantine alone at the same doses  did  not  significantly  inhibit  AChE  activity.  Ex  vivo  data  also  showed  an  acetylcholinesterase (AChE) inhibition of about 50% and 80% with 0.75 mg/kg and 1.5 mg/kg of donepezil, respectively. Pre-treatment with 10 mg/kg of memantine, i.p dose above the clinical relevant exposure in humans (5  mg/kg),  did  not  change  the  activity  of  donepezil  in  either  of  two  tested  regions  (hippocampus, cortex),  dose  well  above  the  clinical  relevant  exposure  in  humans  (5  mg/kg).  The  combination  of donepezil (50 μM) and NMDA  on primary hippocampal neurons showed an elicited response that was about 98% of the response obtained in the absence of donepezil.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacokinetics

No  non  clinical  studies  specifically  investigating  absorption,  distribution,  metabolism,  elimination (ADME)  of  the  combination  (memantine/donepezil)  and  its  drug  interaction  profile  have  been performed.

## 2.3.4. Toxicology

A limited toxicology program has been conducted by the applicant and consisted of one repeated dose toxicology  study  with  the  combination  (memantine/donepezil)  using  the  oral  route.  In  addition,  a single  toxicity  study  was  ongoing  at  the  time  of  submission.  At  the  CHMP  request,  these  data  were subsequently provided during the evaluation.

## 2.3.4.1. Single dose toxicity

Female rats were dosed by oral gavage with 8/0, 30/0, 60/0, 8/5, 60/5, 8/10, 30/10, 60/10, 0/5, or 0/10 mg/kg memantine/donepezil in combination. A vehicle control and a positive control (MK-801, i.p.)  were also included. In addition, one group of rats was dosed once by i.p injection (in the right lower abdominal area) with 30/10 mg/kg memantine/donepezil in combination. There were signs of general toxicity that included decreased activity, anogenital staining, and decreased fecal volume, at 30/10 and 60/10 mg/kg memantine/donepezil, and stain on torso fur and chromodacryrrhea for the 60 mg/kg memantine alone group and at 60/5 mg/kg memantine/donepezil. Mortality was observed for 3 females at  30/10  mg/kg  memantine/ donepezil given i.p.  In  addition,  one  female  receiving  at  60/0 mg/kg memantine/donepezil was found in a moribund condition and euthanized at day 2. This finding was  not  considered  related  to  the  tested  article  and  may  have  been  caused  by  injury  during  a toxicokinetic  blood  collection  from  the  jugular  vein.  No  degeneration  in  the  brain  was  seen  with donepezil alone (5 and 10 mg/kg) and memantine alone at 8 mg/kg. Higher doses, i.e. 30 and 60 mg/kg  memantine  alone  showed  mild  effects.  Memantine  and  donepezil  in  combination  at  30/10 mg/kg caused degeneration in the brain that was present in greater numbers of rats as compared to the  30/0  mg/kg  group  and  was  considered  generally  minimal  in  severity.  There  was  a  substantial potentiation  of  degeneration  in  the  brain  at  60/10  mg/kg.  The  range  of  affected  brain  sites  was markedly greater in rats administered the 60/10 mg/kg as compared to other treatment regimens with severity grades of mostly moderate to marked.

## 2.3.4.2. Repeat dose toxicity

A repeated dose toxicity was conducted for 28 days. Female rats were dosed by oral gavage at levels of 0, 3, 10, 30 and 60 mg/kg/day; donepezil at levels of 0, 3 and 10 mg/kg/day; and the combination of memantine/donepezil at levels of 0/0, 3/3, 10/3, 30/3, 60/3, 0/0, 3/10, 10/10, 30/10 and 60/10 mg/kg/day, according to a specified time schedule. A vehicle control and a positive control (MK-801, i.p.) were also included.

Mortality occurred during the first eight days of dosing. Unscheduled deaths were observed in 1, 1, and 3  rats  in  the  60/0,  30/3  and  60/10  mg/kg/day  memantine/donepezil  combination  dosage  groups, respectively. Necropsy findings for these premature decedents were unremarkable and a lack of test article relationship could not be established. In addition, 2, 2, 1, 4, 1 and 1 animals in the 60/0, 30/3, 30/10, 60/10, 0/3 and 0/10 mg/kg/day memantine/ donepezil combination toxicokinetic (TK) groups were found dead and the cause of death was not determined. Four other unscheduled deaths (1, 2, and  1  rats  in  the  30/0,  3/3  and  10/3  mg/kg/day  memantine/donepezil  combination  groups,

<div style=\"page-break-after: always\"></div>

respectively)  occurred  during  the  study.  These  animals  had  necropsy  findings  compatible  with  a gavage accident. One animal was sacrificed for human reasons after accidental injury.

Stained  fur  (anogenital  stains,  or  otherwise),  excessive  salivation,  lacrimation,  tremors,  decreased activity  and/or  chromodacryorrhea  were  observed  in  the  60/10  mg/kg/day  memantine/donepezil combination group. These clinical signs were also observed, but for a lesser number of days, in the groups receiving 60/3 and 30/10 mg/kg/day of the memantine/ donepezil combination. In the groups given  memantine  alone,  stained  fur  and  chromodacryorrhea  occurred  in  two  animals  in  the  60 mg/kg/day group for a number of days, and infrequently at 30 mg/kg/day. Lacrimation and excessive salivation was recorded infrequently at doses ≥ 30 mg/kg/day.

One, 1, 1 and 2 rats in the 60/0, 60/3, 30/10 and 60/10 mg/kg/day memantine/donepezil combination groups, respectively, had neurodegenerative lesions in one or more regions of the brain. All animals evaluated in the 0.5 and 3 mg/kg dosage groups of MK-801, the positive control, had neurodegeneration in one or more regions of the brain.

Toxicokinetic  data  collected  from  this  study  showed  a  dose-dependent  increase  in  exposure  as memantine  dose  increased.  Increases  in  memantine  maximum  plasma  concentration  (Cmax)  were relatively  dose  proportional  as  memantine  dose  increased  while  increases  in  area under the plasma concentration-time curve from zero to 24 hours post-dose ( AUC0-24) were generally greater than dose proportional.  There  was  some  accumulation  of  memantine  by  day  28,  most  notably  at  30  and  60 mg/kg/day where Cmax and AUC0-24 increases were 2-fold greater than the corresponding day 1. Time to maximum observed concentration (Tmax) was generally between 0.5 and 2 hours and 1 and 4 hours on days 1 and 28, respectively. Mean apparent elimination half life (t½) increased as memantine dose increased, ranging between 3 and 9 hours and 3 and 5 hours on days 1 and 28, respectively. Donepezil exposure was variable with fixed donepezil doses and varying memantine doses, with no clear pattern of exposure increases or decreases correlating with increasing or decreasing memantine doses. Dosedependent increases in exposure were observed as donepezil dose increased. Dose proportionality with donepezil exposure was generally observed with Cmax and AUC0-24  on days 1 and 28. There was no apparent accumulation of donepezil by day 28 at 3 mg/kg/day, however, a slight increase in AUC0-24 was observed on day 28 at 10 mg/kg/day. Tmax was about 0.5- 2 hours at 3 mg/kg/day and 0.5-4 hours at 30 mg/kg/day. T½ was greater on day 1 at both donepezil doses, regardless of memantine dose, than on day 28.

## 2.3.4.3. Genotoxicity

No genotoxicity studies have been performed with the combination (memantine/donepezil).

## 2.3.4.4. Carcinogenicity

No carcinogenicity studies have been performed with the combination (memantine/donepezil).

## 2.3.4.5. Reproduction Toxicity

No reproduction toxicity studies have been performed with the combination (memantine/donepezil).

## 2.3.4.6. Toxicokinetic data

Toxicokinetic data are addressed in the repeated dose toxicity study (see above).

<div style=\"page-break-after: always\"></div>

## 2.3.4.7. Local Tolerance

Single and repeated dose toxicity studies with the combination (memantine/donepezil) addressed local tolerance. No relevant findings were observed.

## 2.3.4.8. Other toxicity studies

No  other  toxicity  studies  have  been  performed  with  the  combination  (memantine/donepezil).  No relevant findings were observed regarding potential for antigenicity and immunotoxicity in the repeated dose toxicity study with the combination (memantine/donepezil).

## 2.3.5. Ecotoxicity/environmental risk assessment

No formal environmental risk assessment (ERA) has been conducted for the combination (memantine/donepezil), in accordance to the EMEA Guideline on the environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00). According to the applicant, Log Kow value  were  respectively  3.28  for  memantine  and  2.3  for  donepezil  at  pH=7.4.  The  PECsw  for memantine and donepezil, using a refined Fpen, were 0.0020 μg/L and 0.0010 μg/L, respectively, and, since both values were below the threshold value (0.01 μg /L), the applicant concluded that a phase II assessment was not required.

However,  having  considered  the  data  submitted  in  the  application,  the  CHMP  did  not  conclude  on whether or not the combination could pose a risk for the environment at this time for the following reasons:

- -The  calculations  used  to  determine  the  pKa  of  donepezil  were  not  fully  provided  by  the applicant to accept its Log Kow value of 3.28;
- -The  calculation  of  the  refined  Fpen  was  determined  using  market  research  data  and  was therefore not acceptable.

## 2.3.6. Discussion on non-clinical aspects

The non clinical programme considered the CHMP guideline on the non-clinical development of fixed combinations of medicinal products (CPMP/SWP/258498/2005) and has been limited to 2 non clinical studies characterising the pharmacology and toxicology profiles of the use of the combination. All other submitted were derived from the literature. The CHMP accepted this approach since this application relates to a fixed combination (memantine 20 mg/donepezil 10 mg) that included compounds for which there was sufficiently documented human experience of their individual and combined use.

In  line  with  effects  of  other  NMDA  antagonists,  available  preclinical  data  suggested  that  memantine increased the synaptic levels of ACh. An effect, which would not be detected by microdialysis method unless  AChEs  were  inhibited.  Additionally,  ACh  levels  may  be  increased  by  different  mechanisms, where memantine increases the release and donepezil reduce the degradation.

Toxicological data were limited to 28 days and showed a slight dose-dependent increase of vacuoles with  memantine.  A  dose-dependent  increase  in  exposure  was  found  as  memantine  dose  increased. Donepezil seemed to potentiate the memantine effect as with the 30 mg/kg dose of memantine alone no  vacuoles  were  observed  but  at  the  same  dose  in  combination  with  donepezil,  vacuolation  was observed in 1/10 animals. The exposures at which mortality was observed were lower than those at which  neurodegeneration  was  reported.  Taken  together,  mortality  in  the  single  dose  toxicity  study occurred at exposures 16 (donepezil) or 54 times (memantine) the human exposure based on Cmax or 6 (donepezil) or 10 times (memantine) the human exposure based on AUC. The safety margins based

<div style=\"page-break-after: always\"></div>

on the highest oral dose without mortality were therefore 10 (donepezil) or 35 (memantine) based on Cmax and 5 (donepezil) or 19 (memantine) based on AUC. Neurotoxicity was observed in the groups receiving memantine and donepezil at doses of 30/0, 60/0, 60/5, 30/10 and 60/10 mg/kg orally or at a dose of 30/10 mg/kg i.p, therefore in all groups receiving memantine at doses of 30 mg/kg or above, irrespective of donepezil co-administration. A potentiation of neurodegeneration regarding the number of  brain  regions  affected  and  the  severity  of  findings  was  mainly  seen  in  the  groups  receiving  the combination at 60/10 mg/kg memantine/donepezil orally and in the group receiving memantine/donepezil  at  a  dose  of  30/10  mg/kg  i.p,  i.e.  at  exposures  well  exceeding  the  clinically relevant exposure. The No Observed Adverse Effect Level (NOAEL) for neurodegeneration under the conditions of this study was 8/5 mg/kg memantine/donepezil. Mortality in the repeated dose toxicity study  occurred  in  1/1/3  animals  at  doses  of  memantine  and  donepezil  at  30/3,  60/0  and  60/10 mg/kg/day. No mortality was seen in the groups receiving the combination at 30/0, 30/10 or 60/3 mg/kg/day suggesting a lack of apparent dose-response relationship for the observed mortality at 30/3 or 60/0 mg/kg memantine/donepezil. Furthermore, there were no clinical signs except for chromodacryorrhea  at  60/0  mg/kg/day  and  no  significant  effects  on  body  weight  were  seen  in  any group. The NOAEL for mortality was considered 30/10 or 60/3 mg/kg/day, based on the lowest dose level  causing  mortality  (60/10  mg/kg/day).  Neurotoxicity  was  seen  in  2  out  of  10  rats  at  60/10 mg/kg/day,  and  in  1  rat  from  each  of  the  groups  receiving  30/10,  60/0  and  60/3  mg/kg/day memantine in combination with donepezil. The minimal dose of the memantine/donepezil combination causing  neurotoxicity  was  30/10  mg/kg/day  or  60/3  mg/kg/day.  Consequently,  the  NOAELs  for neurotoxicity was considered at 30/3 or 10/10 mg/kg/day.

Overall, the calculated safety margins were found to be sometimes low for one component when the exposure  to  the  second  one  was  high,  and  taking  into  account  the  proposed  chronic  clinical  use  of Acrescent. These data could not rule out possible toxic effects in humans at the proposed clinical dose level. During the evaluation, on the basis of these data and the safety profile of the combination, a recommendation was given by the CHMP to complement the toxicological programme with a 3 month toxicity study. However this recommendation was not followed by the applicant on the basis that the absence  of  a  3  months  repeat  dose  toxicity  study  could  be  accepted  if  there  was  experience  of concomitant use according to the guideline on the non-clinical development of fixed combinations of medicinal products (CPMP/SWP/258498/2005). In this regard, the CHMP took into account the clinical safety database including 24 clinical studies (of longer duration than 3 months) and a total of 1626 patients treated with a combination of donepezil and memantine, resulting in a total exposure for the combination of 1523 years and concluded that the applicant justification was acceptable.

## 2.3.7. Conclusion on the non-clinical aspects

Overall, the non-clinical aspects of the combination have been adequately documented and meet the requirements to support this application. However, The CHMP could not conclude on whether or not the combination could pose a risk for the environment since some issues remained unresolved at this time.

## 2.4. Clinical aspects

The clinical  program  considered  the  CHMP  Guideline  on  the  Clinical  Development  of  Fixed  Medicinal Products (CPMP/EWP/240/95, Rev 1) and consisted of:

-A bioequivalence study ( Study  13458A )  that  was  conducted  for  the  new  fixed-combination tablet versus memantine and donepezil tablets taken in combination.

<div style=\"page-break-after: always\"></div>

-An interaction study ( Study MEM-PK-07 ) that was a single-centre, open-label, multiple-dose trial in healthy men and women. The primary objective of the study was to determine whether there is an in vivo pharmacokinetic interaction between memantine and donepezil.

-Twenty  five  clinical  studies,  7  of  them  randomised,  double-blind,  placebo-controlled  studies with memantine including patients (or a subset of patients) concurrently treated with memantine and donepezil.  Of  these  7  studies,  one  ( Study  MEM-MD-02 )  was  designed  to  assess  the  effects  of memantine added to ongoing treatment with donepezil in patients with moderate to severe AD.

-Treatment guidelines and literature to assess the medical environment and current practice for combination treatment,  particularly  with  respect  to  when  and  why  physicians  prescribe  combination treatment.

-Epidemiological  studies  and  prescription  databases  have  been  evaluated  to  document  the evidence of the widespread use of memantine and donepezil in combination in the European Union.

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The  applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies - Table 1

<div style=\"page-break-after: always\"></div>

Table 1

Table 1 Biopharmaceutic Study

| Study, Status, Report Location (Module 5)   | Iype of Study of Control                                                    | FSFV/LSLV StudyDesign&IypeNumber&Location ofSites   | Numberof SubjectsDiagnosis& Treated/CompletedMainInclusion Age (mean), Sex   | Criteria                                                | IMIPs: Dose, Route,&Regimen Treatment   | Duration of Primary   | Endpoints                                                                                                  |
|---------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------|------------------------------------------------------------------------------|---------------------------------------------------------|-----------------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------|
| 13458A Completed                            | Bioequivalence Randomised, open-label, two-sequence, single-dose, crossover | Aug 2010/0ct2010 1 site in UK                       | 29/21 21 to 52 (31) years 20M/9F                                             | Healthy men and MEM: 20mg women, aged ≥18 and ≤55 years | DPZ:10mg Orally                         | 2 single doses        | To evaluate the bioequivalence of the MEM/DPZ combination tablet and the MEM andDPZ tablets taken together |

| Table 2                                   | PharmacokineticandPharmacodynamicStudy                                            | PharmacokineticandPharmacodynamicStudy             | PharmacokineticandPharmacodynamicStudy                                     | PharmacokineticandPharmacodynamicStudy   | PharmacokineticandPharmacodynamicStudy                                      | PharmacokineticandPharmacodynamicStudy   | PharmacokineticandPharmacodynamicStudy                                                              |
|-------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------|------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Study, Status, Report Location (Module 5) | Iype of Study of Control                                                          | FSFV/LSLV StudyDesign&IypeNumber&Location of Sites | Numberof SubjectsDiagnosis& Treated/CompletedMainInclusion Age (mean), Sex | Criteria                                 | IMIPs: Dose, Route,&Regimen Treatment                                       | Duration of Primary                      | Endpoints                                                                                           |
| MEM-PK-07 Completed                       | Pharmacokinetics and Jul2001/Sep 2001 pharmacodynamics Multiple-dose, open- label | 1 site in US                                       | 24/19 18 to 35 (27.6) years 16M/8F                                         |                                          | Healthy subjects MEM: 10mg once 43 days daily DPZ:5or10mg once daily Orally |                                          | To evaluate whether there is an in vivo pharmacokinetic interaction between memantine and donepezil |

## 2.4.2. Pharmacokinetics

No phase I clinical pharmacology studies specifically investigating absorption, distribution, metabolism, elimination (ADME) of the combination (memantine/donepezil) has been conducted. The pharmacokinetic studies consisted of one study investigating the drug interaction profile between the individual components of the fixed combination and another study evaluating the bioequivalence of the fixed combination and the both individual components taken together.

Plasma  concentrations  of  memantine  and  donepezil  were  determined  using  LC/MS/MS  methods. Pharmacokinetic parameters were determined using non compartmental methods. The AChE activity and  inhibition  of  AChE  by  donepezil  in  red  blood  cells  (RBCs)  were  measured  using  a  validated radioenzyme assay.

The pharmacokinetic profile is well known for the individual components and is briefly presented below.

## 2.4.2.1. Absorption

## Memantine

Memantine is well absorbed, with high bioavailability approaching 100%. There is no indication that food influences the absorption of memantine.

## Donepezil

Maximum  plasma  levels  are  reached  approximately  3  to  4  hours  after  oral  administration.  Plasma concentrations  and  area  under  the  curve  rise  in  proportion  to  the  dose.  Food  did  not  affect  the absorption of donepezil hydrochloride.

## 2.4.2.2. Bioequivalence

## Methods

<div style=\"page-break-after: always\"></div>

## Study design

Study  13458A  was  a  single-centre,  randomised,  open-label,  crossover,  bioequivalence,  single-dose study. Treatment consisted of two separate single-dose administrations of 20 mg memantine and 10 mg donepezil under fasting conditions. All subjects were to receive both the test and the reference treatment. The doses were separated by a washout period of 21 to 23 days (see Figure 1).

Figure 1

<!-- image -->

Treatment administration(Day 1,Period 1 and Day 22,Period 2)

The study was conducted in Covance Clinical Research Unit Ltd, United Kingdom. The bioanalytical, pharmacokinetics and statistical facilities were part of H. Lundbeck A/S, Denmark.

Blood samples (2 mL) for pharmacokinetic assessments were drawn at pre-dose, and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 264, and 312 hours post-dose (Periods 1 and 2). Samples were inverted 6 to 8 times and placed on water ice, and were centrifuged (1500 g for 10 min at approximately 4 ºC) within 30 minutes of collection. The samples were frozen at -20 ºC within 2 hours of collection. Samples were shipped frozen packed with sufficient quantities of dry ice to ensure that they remained frozen during transportation.

## Test and Reference products

These are presented in Table 2.

Table 2

| Tablet                                             | Batch Number   | Expiry Date   |
|----------------------------------------------------|----------------|---------------|
| 20mg gmemantine/10 mg donepezil combination tablet | 4320203T       | Jan 2011      |
| 20 mg memantine tablet                             | 91250          | Dec 2010      |
| 10 mg donepezil tablet                             | 100543         | Dec 2010      |

## Population studied

A total of 24 men and women (approximately equal numbers of men and women) aged between 18 and  55  years  inclusive,  with  a  body  mass  index  (BMI)  between  19  and  30  kg/m2  inclusive  were planned for enrolment.

<div style=\"page-break-after: always\"></div>

A total  of  29  subjects  were  randomised  into  the  study.  A  total  of  21  subjects  completed  the  study. Eight subjects (all women) withdrew due to adverse events.

The following subjects withdrew in Period 1:

- 2 subjects who received the test treatment in Period 1 both withdrew on Day 1, due to adverse events of vomiting.
- 3 subjects who received the reference treatment in Period 1, 2 withdrew due to adverse events of vomiting and 1 withdrew due to upper abdominal pain on Days 1, 1, and 4, respectively.

The following subjects withdrew in Period 2:

- 1 subject, who received the reference treatment in Period 1 and the test treatment in Period 2, withdrew due to an adverse event of upper abdominal pain on Day 27 (Period 2).
- 2 subjects, who received the test (Period 1) and the reference (Period 2) treatment; withdrew due  to  adverse  events  of  paraesthesia  and  upper  abdominal  pain;  on  Days  28  and  23, respectively.

All subjects who withdrew in Period 1 were replaced. None of the subjects who withdrew in Period 2 were replaced.

## Results

These are presented in Figures 2-5 and Table 3-4.

Figures 2 and 3. Median (and Quartiles) Plasma Concentrations of Memantine Following the Singledose Administration of 20 mg Memantine and 10 mg Donepezil as a Combined Tablet (Test) and as Individual Tablets (Reference)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figures  4  and  5 .  Median (and Quartiles) Plasma Concentrations of Donepezil Following the Singledose Administration of 20 mg Memantine and 10 mg Donepezil as a Combined Tablet (Test) and as Individual Tablets (Reference)

<!-- image -->

<!-- image -->

Semi-logarithmic scale

<div style=\"page-break-after: always\"></div>

Table 3 .Pharmacokinetic parameters of memantine (completer set)

| Parameter            | 20 mg Memantine/ 10 mg Donepezil Combined Tablet (Test) N=21   | 20 mg Mfemantine/ 10 mg Donepezil Individual Tablets (Reference) N=21   | Estimated Ratio (90% CI)#   |
|----------------------|----------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------|
| AUCo-72 h (ng-h/mL)a | 1055 (11.7)                                                    | 1081 (13.3)                                                             | 97.7 (95.3, 100.1)          |
| Cmax (ng/mL)a        | 23.5 (13.6)                                                    | 24.4 (16.1)                                                             | 96.4 (93.1,99.9)            |
| AUCo-mf (ng-h/mL)    | 2009 (16.5)                                                    | 2088 (16.0)                                                             | 96.0 (93.1, 99.0)           |
| AUCo- (ng-h/mL)      | 1917 (15.4)                                                    | 1994 (15.7)                                                             | 96.0 (93.2, 98.8)           |
| AUC%extap (%)        | 4.43 (35.9)                                                    | 4.43 (40.3)                                                             | NC                          |
| tmax (h)a            | 5.00 (2.00, 8.00)                                              | 6.00 (1.00, 8.00)                                                       | 107.2                       |
| t (h)                | 67.1 (13.8)                                                    | 67.1 (14.3)                                                             | 100.0                       |
| CL/F (L/h)           | 10.2 (16.3)                                                    | 9.81 (16.2)                                                             | 104.2                       |
| V/F (L)              | 973 (11.9)                                                     | 938 (13.3)                                                              | 104.2                       |

Arithmetic mean (CV%) values are presented for AUCo-72 h. Cmx, AUCo-it, AUCo-t AUC%extap. t4g, CL/F, and

Median (min, max) values are presented for tmax

V,/F.

N = number of subjects

NC = not calculated

# CIs are presented for primary pharmacokinetic parameters.

aN=23

Table 4. Pharmacokinetic parameters of donepezil (completer set)

| Parameter           | 20 mg Memantine/ 10 mg Donepezil Combined Tablet (Iest) N=21   | 20 mg MIemantine/ 10 mg Donepezil Individual Tablets (Reference) N=21   | Estimated Ratio (90% CI)   |
|---------------------|----------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------|
| AUCo-72 h (ng-h/mL) | 401 (24.9)                                                     | 418 (23.6)                                                              | 95.5 (93.5, 97.6)          |
| Cmax (ng/mL)a       | 15.5 (23.6)                                                    | 17.2 (26.7)                                                             | 90.6 (85.4, 96.2)          |
| AUCo-inf (ng-h/mL)a | 762 (42.1)                                                     | 790 (35.8)                                                              | 95.0 (92.1, 97.9)          |
| AUCo-t (ng-h/mL)    | 692 (35.1)                                                     | 728 (31.9)                                                              | 94.4 (91.8, 97.1)          |
| AUC%extap (%)       | 7.48 (73.0)                                                    | 6.95 (64.5)                                                             | NC                         |
| tmax (h)a           | 2.00 (1.00, 5.00)                                              | 2.00 (1.00, 5.00)                                                       | 103.9                      |
| ty (h)              | 79.8 (28.5)                                                    | 78.9 (26.3)                                                             | 100.5                      |
| CL/F (L/h)          | 14.9 (33.0)                                                    | 14.1 (33.0)                                                             | 105.3                      |
| V/F (L)             | 1610 (21.9)                                                    | 1521 (23.2)                                                             | 105.9                      |

Arithmetic mean (CV%) values are presented for AUCo-72 h. Cmax. AUCo-inf, AUCot, AUC%extap, t4, CL/F, and

Median (min, max) values are presented for tmax-

V/F.

N = number of subjects

NC = not calculated

# CIs are presented for primary pharmacokinetic parameters.

aN=23

## 2.4.2.3. Distribution

## Memantine

Daily doses of 20 mg lead to steady-state plasma concentrations of memantine ranging from 70 to 150 ng/ml  (0.5  -  1 μmol) with large interindividual variations. When daily doses of 5 to 30 mg were administered,  a  mean  cerebrospinal  fluid  (CSF)/serum  ratio  of  0.52  was  calculated.  The  volume  of distribution is around 10 l/kg. About 45% of memantine is bound to plasma-proteins.

<div style=\"page-break-after: always\"></div>

## Donepezil

The distribution of donepezil hydrochloride in various body tissues has not been definitively studied. However,  in  a  mass  balance  study  conducted  in  healthy  male  volunteers,  240  hours  after  the administration of a single 5 mg dose of 14C-labeled donepezil hydrochloride, approximately 28% of the label  remained  unrecovered.  The  terminal  disposition  half-life  is  approximately  70  hours,  thus, administration  of  multiple  single-daily  doses  results  in  gradual  approach  to  steady-state.  Donepezil hydrochloride is approximately 95% bound to human plasma proteins. The plasma protein binding of the active metabolite 6-O-desmethyldonepezil is not known.

## 2.4.2.4. Elimination

## Memantine

Memantine is mainly excreted unchanged in the urine (60-80%) and its terminal half-life is 60 to 100 h. In volunteers with normal kidney function, total clearance (Cltot) amounts to 170 ml/min/1.73 m² and part of total renal clearance is achieved by tubular secretion.

Renal handling also involves tubular reabsorption, probably mediated by cation transport proteins. The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 (see section 4.4). Alkalisation of urine may result from drastic changes in diet, e.g. from a carnivore to a vegetarian diet, or from the massive ingestion of alkalising gastric buffers.

## Donepezil

Approximately  57%  of  the  total  administered  radioactivity  was  recovered  from  the  urine  (17%  as unchanged donepezil), and 14.5% was recovered from the faeces, suggesting biotransformation and urinary excretion as the primary routes of elimination. There is no evidence to suggest enterohepatic recirculation of donepezil hydrochloride and/or any of its metabolites.

## 2.4.2.5. Dose proportionality and time dependencies

## Memantine

Cmax following a single 20 mg oral dose of memantine ranges between 22 and 46 ng/ml. Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg.

## Donepezil

Plasma concentrations and area under the curve rise in proportion to the dose.

## 2.4.2.6. Special populations

No  pharmacokinetic  studies  in  special  population  have  been  performed  with  the  combination (memantine/donepezil).

## 2.4.2.7. Pharmacokinetic interaction studies

Study MEM-PK-07 was a single-centre, open-label, multiple-dose study in healthy men and women. The  primary  objective  of  the  study  was  to  determine  whether  there  is  an  in  vivo  pharmacokinetic interaction between donepezil on memantine. The secondary objective was to determine whether coadministration of memantine affects the ability of donepezil to inhibit AChE activity in RBCs

For  all  subjects:  on  Day  1,  a  single  dose  of  10  mg  memantine  was  administered.  After  a  14-day washout period, 5 mg/day donepezil for 7 days (Days 15 to 21) and then 10 mg/day donepezil for 22

<div style=\"page-break-after: always\"></div>

days  (Days  22  to  43).  In  the  morning  of  the  last  day  of  donepezil  treatment  (Day  43),  10  mg memantine was also given.

Twenty-four subjects (16 males and 8 females) were enrolled and 19 subjects completed the study. Results are shown in Tables 5 and 6.

Table  5. Comparative  pharmacokinetic  profile  of  memantine  when  administered  alone  or  with donepezil at Day 1

| Parameter                                 | WithoutDonepezil (N =19)                  | WithDonepezil (N =19)                     |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Cmax (ng/mL)                              | 12.8±2.4                                  | 13.0± 2.0                                 |
| tmax (h)                                  | 6.5 ±2.1                                  | 6.5 ± 1.3                                 |
| AUCo-t (ng·h/mL)                          | 958 ± 147                                 | 1003 ± 143                                |
| AUCo-inf (ng:h/mL)                        | 1125±211                                  | 1188±223                                  |
| ty: (h)                                   | 70.9 ±24.1                                | 72.3 ± 16.3                               |
| CL/F (mL/min)                             | 127±23.8                                  | 120±21.2                                  |
| V,/F (L)                                  | 760±202                                   | 735± 128                                  |
| MRT (h)                                   | 98.9 ±29.8                                | 101 ± 19.5                                |
| Arithmeticmean (±SD)values are presented. | Arithmeticmean (±SD)values are presented. | Arithmeticmean (±SD)values are presented. |

The 90% CIs for the least squares means ratios for the log-transformed Cmax, AUC0-t, and AUC0-inf for memantine were within the acceptance range of 80% to 125% (CI:98.6-105.4; 101.6-108.1, and 102-109.7, respectively ). These data indicated that multiple daily dosing with 10mg donepezil did not significantly affect the rate or extent of absorption of a single dose of 10mg memantine.

Table 6 Comparative pharmacokinetic profile of donepezil when administered alone or with memantine at Day 42

| Parameter                                    | WithoutMIemantine (N = 19)                   | WithMemantine (N = 19)                       |
|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Cmax ( (ng/mL)                               | 49.1 ±14.5                                   | 55.4 ± 18.0                                  |
| (h)                                          | 3.4 ± 1.5                                    | 3.3± 1.7                                     |
| AUCo-24h (ng:h/mL)                           | 858±247                                      | 934±250                                      |
| CL/F (mL/min)                                | 215 ±175                                     | 182±91.5                                     |
| Arithmetic mean (± SD) values are presented. | Arithmetic mean (± SD) values are presented. | Arithmetic mean (± SD) values are presented. |

The 90% CI for the least squares means ratio for the log-transformed AUC0-24h for donepezil was within the acceptance range of 80% to 125% (CI:105.1-117.3), indicating that single dosing with 10 mg  memantine  did  not  significantly  affect  the  extent  of  absorption  of  multiple  doses  of  10  mg donepezil. However, the 90% CI for the least squares means ratio for the log-transformed Cmax was outside the acceptance range (104.2-126.5%). A re-analysis was performed excluding 4 subjects who did not attained steady state by Day 42 and both 90%CI for the least squares means ratio for the logtransformed  AUC0-24h  and  Cmax  were  found  within  the  acceptance  range  (CI:99.7-124.8;  101.8116.6, respectively).

## 2.4.2.8. Pharmacokinetics using human biomaterials

No  pharmacokinetic  studies  using  human  biomaterials  have  been  performed  with  the  combination (memantine/donepezil).

<div style=\"page-break-after: always\"></div>

## 2.4.3. Pharmacodynamics

## 2.4.3.1. Mechanism of action

Acrescent  is  a  combination  product  containing  two  compounds  with  different  mechanisms  of  action considered as 'complementary': memantine is an NMDA receptor antagonist and donepezil belongs to the class of acetylcholinesterase inhibitors. This combination product is claimed to be commonly used as  therapy  for  the  treatment  of  moderate  to  moderately  severe  Alzheimer's  disease.  Acrescent  is intended to simplify the treatment regimen for patients who are already on a stable daily dose of 20 mg  memantine  and  10  mg  donepezil.  This  would  provide  the  opportunity  to  improve  patient compliance and persistence with the treatment.

## Memantine

There is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at NMDA-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative  dementia.  Memantine  is  a  voltage-dependent,  moderate-affinity  uncompetitive NMDA-receptor antagonist. It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.

## Donepezil

Donepezil is a specific and reversible inhibitor of acetylcholinesterase, the predominant cholinesterase in  the  brain.  Donepezil  hydrochloride  is  in  vitro  over  1000  times  more  potent  an  inhibitor  of  this enzyme than of butyrylcholinesterase, an enzyme that is present mainly outside the central nervous system.

## 2.4.3.2. Primary and Secondary pharmacology

No primary and secondary pharmacology studies in man have been performed with the combination (memantine/donepezil).  However  the  pharmacodynamic  interaction  profile  was  studied  in  the  study MEM-PK-07, previously described (see 2.4.2.7). Results are presented in Table 7.

Table 7 Comparative pharmacodynamic profile of donepezil when administered alone (Day 42) or with memantine (Day 43)

| Parametel                                   | WithoutMemantine (N =19)                    | WithMemantine (N = 19)                      |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Imax (%of baseline)                         | 77.8±7.3                                    | 81.1±5.7                                    |
| AUC (% of baseline-h)                       | 1708±191                                    | 1785±169                                    |
| Arithmeticmean (± SD) values are presented. | Arithmeticmean (± SD) values are presented. | Arithmeticmean (± SD) values are presented. |

The 90% CIs for the least squares means ratios for the log-transformed Imax and AUCI were within the  acceptance  range  of  80%  to  125%  (CI:101.8-107.1;102.7-106.9,  respectively)  indicating  that inhibition  of  RBCs  AChE activity  was not  significantly  affected  by  co-administration  of  donepezil  and memantine compared to administration of donepezil alone.

## 2.4.4. Discussion on clinical pharmacology

The  pharmacokinetic  data  provided  considered  the  CHMP  Guideline  on  the  Clinical  Development  of Fixed Medicinal Products (CPMP/EWP/240/95, Rev 1) and consisted of bioequivalence study (13458A) between the free combination of the recognised reference formulations of the individual monocomponents  and  the  marketing  formulation  (fixed  combination)  together  with  an  interaction

<div style=\"page-break-after: always\"></div>

study  (MEM-PK-07)  to  evaluate  pharmacokinetic  interaction  between  memantine  and  donepezil  and also examine the pharmacodynamic effect of memantine co-administration on the potential inhibition of AChE activity by donepezil in RBCs. According to the applicant, both memantine and donepezil were considered Biopharmaceutics Classification System (BCS) class I substances (high solubility and high absorption). The pharmaceutical form of the proposed fixed combination tablet is an immediate-release tablet  for  oral  administration.  The  excipients  in  the  formulation  were  considered  all  well-established excipients and similar to those used in the reference products.

Bioequivalence was  demonstrated  between  the  fixed combination applied for  (memantine  20 mg/donepezil 10 mg) and the free combination of the recognised reference formulations of memantine 20 mg and donepezil 10 mg.

When  a  single  dose  of  memantine  was  administered  alone  or  in  combination  with  donepezil (10 mg/day),  donepezil  did  not  show  an  effect  on  the  pharmacokinetics  of  memantine.  The  % maximum inhibition of AChE activity from baseline averaged from 77.8% to and 81.1% for donepezil when administered with or without memantine suggesting no pharmacodynamic interaction between the  2  components  when  concomitantly  used.  Since  the  two  compounds  share  different  metabolic pathways, no metabolic interaction between memantine and donepezil was expected. Hence the CHMP considered  acceptable  that  the  design  of  this  study  did  not  investigate  the  interaction  effect  with memantine at steady state.

## 2.4.5. Conclusions on clinical pharmacology

Overall,  the  pharmacological  profile  of  the  combination  in  human  studies  has  been  adequately documented and meet the requirements to support this application.

## 2.5. Clinical efficacy

Twenty  five  clinical  studies,  7  of  them  randomised,  double-blind,  placebo-controlled  studies  with memantine  including  patients  (or  a  subset  of  patients)  concurrently  treated  with  memantine  and donepezil  were  submitted  to  support  the  clinical  efficacy  of  the  fixed  combination  (memantine  20 mg/donepezil 10 mg) in the indication applied for (moderate to moderately severe AD). Of these 7 studies, one (Study MEM-MD-02) was designed to assess the effects of memantine added to ongoing treatment with donepezil in patients with moderate to severe AD.

In  addition,  a  bibliographical  analysis  was  submitted  to  claim  a  widespread  use  of  the  combination (memantine/donepezil) and support the reduced amount of clinical data submitted in this application. This  analysis  consisted  of  available  treatment  guidelines/expert  panel  recommendations,  published studies  (including  clinical,  observational  and  market  research  data)  and  included  a  review  of epidemiological, market research and prescription data.

## 2.5.1. Dose response study

No dose response study has been performed with the combination (memantine/donepezil).

## 2.5.2. Main studies

A tabular overview of the 7 clinical studies is presented in Table 8.

<div style=\"page-break-after: always\"></div>

Table 8

Panel 1 Overviewof Randomised,Double-blind,Placebo-controlledStudiesinAD

|                         |                                                                            |                                                                   | Number of Patients Treated                      | Number of Patients Treated                             |
|-------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------|--------------------------------------------------------|
| Study ID                | Study Duration and MEMDose                                                 | AD Severity                                                       | PBO/AChEI (Number of                            | MEM/AChEI (Number of Patients on DPZ) Patients on DPZ) |
| DPZ -a pre-requisite    | DPZ -a pre-requisite                                                       | DPZ -a pre-requisite                                              | DPZ -a pre-requisite                            | DPZ -a pre-requisite                                   |
|                         | MEM-MD-02 24 weeks, MEM 20mg/day, ongoing treatment withDPZ                | Moderatetosevere (MMSE: ≥5 to ≤14)                                | 201 (201)                                       | 202 (202)                                              |
| AChEIs -a pre-requisite | AChEIs -a pre-requisite                                                    | AChEIs -a pre-requisite                                           | AChEIs -a pre-requisite                         | AChEIs -a pre-requisite                                |
|                         | MEM-MD-12 24 weeks, MEM 20mg/day, ongoing treatment with any AChEI         | Mild to moderate (MMSE: ≥10 to ≤22)                               | 216 (137)                                       | 217 (154)                                              |
|                         | MEM-MD-23 12 weeks, MEM 20mg/day. ongoingtreatmentwithany AChEI            | Moderate to severe (with symptoms of agitation) (MMSE: ≥3 to ≤18) | 17 (14)                                         | 17 (17)                                                |
| AChEIs-allowed          | AChEIs-allowed                                                             | AChEIs-allowed                                                    | PBO (Number of Patients on DPZ)Patients on DPZ) | MEM (Number of                                         |
| 10158a                  | 24 weeks, MEM 20 mg/day, ongoing treatment with any AChEI (DPZ,GAL,or RIV) | Moderate to severe (with behavioural symptoms) (MMSE: ≥5 to ≤15)  | 187 (78)                                        | 182 (68)                                               |
|                         | MEM-MD-22 24 weeks, MEM 20 mg/day, nursing home residents                  | Moderatetosevere (MMSE:≥5to≤18)                                   | 132 (47)                                        | 133 (49)                                               |
|                         | MEM-MD-71 12 weeks, MEM 20 mg/day                                          | Moderate (MMSE: ≥10 to ≤19)                                       | 129 (39)                                        | 135 (44)                                               |
| 10112                   | 52 weeks, MEM 20 mg/day                                                    | Moderate (MIMSE: ≥12 to≤20)                                       | 144 (65)                                        | 133 (57)                                               |

MEM: memantine; PBO: placebo; AChEI: acetylcholinesterase inhibitor; DPZ: donepezil; GAL:galantamine;RIV:rivastigmine

aThe originalprotocol forStudy10158(07-Jul-2003) allowed concomitant treatment withAChEIs. Substantial Protocol Amendment SA07 (04-Sep-2009) changed this to a pre-requisite. The study was terminated,andonly afewpatientswereenrolledinthestudyaftertheamendmentcameintoeffect.

## 1) STUDY MEM-MD-02

This was a prospective randomized, double-blind, placebo-controlled, parallel group, fixed-dose trial in which  patients  with  moderate  to  severe  AD  were  assigned  to  memantine/donepezil  treatment  or placebo/donepezil treatment for 24 weeks.

## Method

## Inclusion criteria

Patients  with  a  diagnosis  of  probable  Alzheimer's  disease  consistent  with  National  Institute  of Neurological  and  Communicative  Disorders  and  Stroke  -  Alzheimer's  Disease  and  Related  Disorders Association (NINCDS-ADRDA)  Criteria, a magnetic resonance imaging (MRI) or computerised tomography (CT) scan within the past 12 months with results consistent with the diagnosis of probable Alzheimer's disease, and a Mini Mental State Examination Score (MMSE) of 5 to 14 at both screening and baseline were included. Ongoing daily donepezil therapy for more than 6 months before entrance into the trial and at a stable dose (5-10 mg/day) was required.

## Outcomes/endpoints

The two primary efficacy parameters were the changes from baseline to Week 24 in the total Severe Impairment Battery (SIB Total score, a scale developed for the evaluation of the severity of cognitive dysfunction)  and  the  modified  Alzheimer's  Disease  Cooperative  Study  -  Activities  of  Daily  Living Inventory (ADCS-ADL modified score, focused on the performance of activities of daily living) on the ITT population and using the last observation carried forward (LOCF) approach. The modified ADCSADL is a 19-item subset of the 42-item scale.

<div style=\"page-break-after: always\"></div>

Secondary  efficacy  parameters  included  the  following:  CIBIC-Plus  score  (Clinician's  Interview-based Impression of Change - Plus version), total NPI (Neuropsychiatric Inventory score and subscales, FAST (Functional Assessment Staging), total BGP (Behavioral Rating Scale for Geriatric Patients) score and BGP care dependency and BGP cognitive subscales.

## Results

Out of 404 patients randomized, 403 patients received double-blind treatment. Among these patients, 197 in the placebo/donepezil treatment group and 198 in the memantine/donepezil treatment group were included in the ITT population.

There were no clinically important differences between the treatment groups with regard to baseline demographic  characteristics  or  disease  severity.  The  study  population  was  65%  female  and  91% Caucasian. The mean patient age was 76 years. Mean MMSE score at baseline was 10.

At Week 24, a statistically significant and clinically relevant benefit for memantine/donepezil treatment relative to placebo/donepezil treatment was observed for the modified ADCS-ADL, SIB, and CIBIC-Plus scores.  Patients  treated  with  memantine/donepezil  demonstrated  a  numerical  improvement  in cognitive  performance  scores  relative  to  baseline  values  over  the  24-week  course  of  the  study, whereas  patients  receiving  placebo/donepezil  exhibited  progressive  cognitive  decline  over  the  same period.  Results  from  other  secondary  efficacy  parameters,  including  the  BGP  and  the  NPI,  provided further evidence for the efficacy of memantine in the treatment of moderate to severe dementia.

Results are presented in Tables 9 and 10.

## Table 9

## Table 10

| Panel 14. SummaryofEfficacyResults                    | Panel 14. SummaryofEfficacyResults                    | Panel 14. SummaryofEfficacyResults                    | Panel 14. SummaryofEfficacyResults                    |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Variable                                              | Placebo/ Donepezil                                    | Memantine /Donepezil                                  | p-valne                                               |
| WEEK24 (L0CF)                                         |                                                       |                                                       |                                                       |
| SIBLSmeanchange                                       | -2.5                                                  | 0.9                                                   | <0.001                                                |
| ADCS-ADLLSmean change                                 | -3.4                                                  | -2.0                                                  | 0.028                                                 |
| CIBIC-Plusmean                                        | 4.66                                                  | 4.41                                                  | 0.027                                                 |
| WEEK24 (0C)                                           |                                                       |                                                       |                                                       |
| SIBLSmeanchange                                       | -2.4                                                  | 1.0                                                   | <0.001                                                |
| ADCS-ADLLSmean change                                 | -3.3                                                  | -1.7                                                  | 0.020                                                 |
| CIBIC-Plusmean                                        | 4.64                                                  | 4.38                                                  | 0.028                                                 |
| Cross reference:Tables 3.1,3.2,and 3.3 ITT population | Cross reference:Tables 3.1,3.2,and 3.3 ITT population | Cross reference:Tables 3.1,3.2,and 3.3 ITT population | Cross reference:Tables 3.1,3.2,and 3.3 ITT population |

| Panell3.                       | LSMeanChangefromBaselinetoWeek24(LOCF)inOther SecondaryEfficacyParameter's   | LSMeanChangefromBaselinetoWeek24(LOCF)inOther SecondaryEfficacyParameter's   | LSMeanChangefromBaselinetoWeek24(LOCF)inOther SecondaryEfficacyParameter's   |
|--------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
|                                | Placebo/Donepezil                                                            | Memantine/Donepezil                                                          | pvalue                                                                       |
| NPI                            | 3.7                                                                          | -0.1                                                                         | 0.002                                                                        |
| FAST                           | 0.4                                                                          | 0.4                                                                          | 0.990                                                                        |
| BGP (Total)                    | 3.3                                                                          | 1.1                                                                          | <0.001                                                                       |
| BGP(CareDependency)            | 2.3                                                                          | 0.8                                                                          | 0.001                                                                        |
| BGP (Cognitive)                | 0.5                                                                          | 0.2                                                                          | 0.035                                                                        |
| Cross-reference:Tables3.4to3.8 | Cross-reference:Tables3.4to3.8                                               | Cross-reference:Tables3.4to3.8                                               | Cross-reference:Tables3.4to3.8                                               |

## 2) STUDY MEM-MD-12

<div style=\"page-break-after: always\"></div>

This  was  a  24-week,  randomised,  double-blind,  placebo-controlled,  fixed-dose  study  evaluating  the safety  and  efficacy  of  memantine  (20  mg  once  daily)  compared  to  placebo  in  patients  with  mild  to moderate Alzheimer's Disease currently receiving AChE inhibitors for at least six months.

## Method

## Inclusion criteria

Patients  with  a  primary  diagnosis  of  probable  AD,  a  baseline  MMSE  score ≥ 10  and ≤ 22,  a  baseline Hachinski Ischaemia Scale (HIS) score ≤ 4, and a CT or MRI performed ≤ 12 months prior to screening, confirming  the  diagnosis  of  probable  AD  were  recruited.  The  patients  were  required  to  have  a Montgomery and Åsberg Depression Rating Scale (MADRS) total score &lt;22 at screening. The patients were  required  to  have  been  on  AChEI  treatment  (donepezil,  rivastigmine,  or  galantamine)  for ≥ 6 months prior to study start, and at a stable dose for ≥ 3 months.

## Outcomes/endpoints

The  primary  efficacy  analyses  were  the  mean  changes  from  baseline  in  AD  Assessment  Scale  Cognitive Subscale (ADAS-cog) total score and the mean CIBIC-plus score at Week 24, based on the ITT population and using the LOCF approach.

## Results

A total of 427 patients were included in the ITT population: 214 in the memantine/AChEI group and 213 in the placebo/AChEI group. A total of 291 patients were on concurrent treatment with donepezil during the study: 154 (71%, all patients treated set: APTS) in the memantine/AChEI group and 137 (63%)  in  the  placebo/AChEI  group.  The  mean  baseline  ADAS-cog  and  CIBIC-plus  scores  were approximately 27 and 3.9, respectively, in both treatment groups. A total of 48 patients (11%, APTS) withdrew  from  the  study:  23  (11%)  in  the  memantine/AChEI  group  and  25  (12%)  in  the placebo/AChEI group.

The mean change from baseline in the ADAS-cog total score numerically favoured the memantine/AChEI-treated group compared to the placebo/AChEI-treated group at all visits, using the LOCF analysis. This between-treatment difference was not statistically significant.

Results are presented in Table 11.

## Table 11

Table ll-l. Least Square Mlean Change (SE) From Baseline in ADAS-cog

<!-- image -->

| Timepoint             | Placebo               | Placebo               | Memantine             | Memantine             | LSMeal Difference     | p-valuea              |
|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Timepoint             | N                     | Mean                  | N                     | Mean                  |                       |                       |
| BaselineMean±SD       | 212                   | 26.8±9.88             | 212                   | 27.9± 10.98           |                       |                       |
| LeastSquareMeanChange | LeastSquareMeanChange | LeastSquareMeanChange | LeastSquareMeanChange | LeastSquareMeanChange | LeastSquareMeanChange | LeastSquareMeanChange |
| Week24LOCF(SE)        | 213                   | 0.8 (0.45)            | 214                   | 0.1 (0.45)            | -0.7                  | 0.184                 |
| Week 24 0C (SE)       | 188                   | 0.8 (0.47)            | 192                   | 0.0 (0.48)            | -0.8                  | 0.186                 |

p-value is based on theresults of anANCOVA model with treatment group and study center as factors, and Baseline value ascovariate.

ITTPopulation

CrossReference:Section14.1Table5.1

There  was  no  statistically  significant  difference  between  the  memantine/AChEI-treated  patients compared to the placebo-treated patients in the CIBIC-Plus score using either the LOCF or OC analysis.

## 3) Study MEM-MD-23

<div style=\"page-break-after: always\"></div>

This was a 12-week, randomised, double-blind, placebo-controlled, fixed-dose study.

## Method

## Inclusion criteria

Patients aged ≥ 50 years, with a primary diagnosis of probable AD, a baseline MMSE score ≥ 3 and ≤ 18, and  an  NPI  agitation/aggression  score ≥ 4  at  screening  and  baseline.  Patients  who  were  taking  an atypical antipsychotic at baseline had to have been on a stable dose for &gt;1month prior to enrolment. The patients were required to have been on stable treatment with AChEIs for ≥ 3 months prior to study start.

## Outcomes/endpoints

The primary efficacy analysis was the mean change from baseline in NPI total score at Week 12, based on the ITT population and using the LOCF approach. The secondary efficacy analyses were based on the  ADCS-ADL  total  score,  NPI  agitation/aggression  score,  Clinical  Global  Impression  -  Severity  of Illness (CGI-S) and- Global Improvement (CGI-I) scores, Cohen Mansfield Agitation Inventory (CMAI) score, and Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) score.

## Results

The study was terminated due to poor patient enrolment. A total of 33 patients (of the 150 planned) were included in the ITT population: 17 in the memantine/AChEI group and 16 in the placebo/AChEI group. A total of 31 patients were on concurrent treatment with donepezil during the study: 17 (100%, APTS) in the memantine/AChEI group and 14 (82%) in the placebo/AChEI group. A total of 4 patients (12%,  APTS)  withdrew  from  the  study:  2  (12%)  in  each  treatment  group.  Because  the  study  was terminated, no statistical analyses were performed, and no conclusions could be drawn.

## 4) Study 10158

This  was  a  24-week,  randomised,  double-blind,  placebo-controlled,  fixed-dose  study  examining  the efficacy  and  safety  of  memantine  in  patients  with  moderate  to  severe  dementia  of  the  Alzheimer's type.

## Method

## Inclusion criteria

The patients were outpatients, aged ≥ 50 years, with a primary diagnosis of probable AD, a baseline MMSE  score ≥ 5  and ≤ 15,  a  baseline  HIS  score ≤ 4,  and  an  NPI  total  score ≥ 13  and  NPI agitation/aggression score ≥ 1 at screening and baseline. The protocol was amended to make treatment with an AChEI a pre-requisite.

## Outcomes/endpoints

The primary efficacy analyses were the mean changes from baseline in NPI total score and SIB total score at Week 24, based on the full analysis set (FAS) and using the LOCF approach. The secondary efficacy analyses included the CIBIC-plus score, ADCS-ADL total score, NPI single-item scores, CMAI score, Health Status Questionnaire (HSQ-12; patient and caregiver) scores, and Resource Utilization in Dementia (RUD) total score.

## Results

A total of 324 patients (of the 450 planned) were included in the FAS: 159 in the memantine group and 165 in the placebo group. A total of 146 patients were on concurrent treatment with donepezil during the study: 68 (37%, APTS) in the memantine group and 78 (42%) in the placebo group. The

<div style=\"page-break-after: always\"></div>

mean baseline NPI and SIB total scores were approximately 30 and 82, respectively, in both treatment groups.  A  total  of  63  patients  (17%,  APTS)  withdrew  from  the  study:  31  (17%)  in  the  memantine group and 32 (17%) in the placebo group. There were no statistically significant differences between the treatment groups on the NPI or the SIB total scores at Week 24.

Results are presented in Table 12 and 13

## Table 12

## Table 13

Table 8

NPIMeanTotalScore(FAS,LOCF)

| Treatment Group                                                      | Week     | n   | Mean   | SD    | MedianMinimumMaximum   | MedianMinimumMaximum   | MedianMinimumMaximum   |
|----------------------------------------------------------------------|----------|-----|--------|-------|------------------------|------------------------|------------------------|
| PBO                                                                  | Screen   | 165 | 30.72  | 13.99 | 27.00                  | 5                      | 71                     |
|                                                                      | Baseline | 165 | 29.18  | 13.27 | 26.00                  | 7                      | 80                     |
|                                                                      | Week4    | 161 | 23.17  | 13.01 | 20.00                  | 0                      | 61                     |
|                                                                      | Week 8   | 162 | 23.06  | 15.66 | 20.00                  | 0                      | 72                     |
|                                                                      | Week （12 | 162 | 22.04  | 15.04 | 19.00                  | 1                      | 72                     |
|                                                                      | Week 18  | 162 | 23.43  | 16.18 | 20.00                  | 0                      | 69                     |
|                                                                      | Week24   | 162 | 22.31  | 16.28 | 19.00                  | 0                      | 72                     |
| MEM                                                                  | Screen   | 159 | 31.75  | 14.05 | 30.00                  | 9                      | 87                     |
|                                                                      | Baseline | 159 | 30.94  | 14.79 | 26.00                  | 5                      | 89                     |
|                                                                      | Week4    | 156 | 27.50  | 15.76 | 23.00                  | 0                      | 89                     |
|                                                                      | Week8    | 156 | 24.59  | 17.13 | 21.00                  | 0                      | 89                     |
|                                                                      | Week12   | 156 | 23.90  | 16.53 | 20.00                  | 0                      | 77                     |
|                                                                      | Week 18  | 156 | 24.60  | 16.98 | 21.50                  | 0                      | 95                     |
|                                                                      | Week24   | 156 | 23.77  | 15.64 | 20.00                  | 0                      | 77                     |
| DRAFT10158ETNPI02L0CF18APR2011:13:45:451001/175-TFL/SADBui1d Numbers |          |     |        |       |                        |                        |                        |

Table10 SIB Mean Total Score (FAS, LOCF)

| Treatment Group                                                 | Week     | n   | Mean   | SD    | MedianMinimumMaximum   | MedianMinimumMaximum   | MedianMinimumMaximum   |
|-----------------------------------------------------------------|----------|-----|--------|-------|------------------------|------------------------|------------------------|
| PBO                                                             | Baseline | 165 | 81.98  | 12.86 | 85.00                  | 22                     | 98                     |
|                                                                 | Week12   | 155 | 81.03  | 15.48 | 86.00                  | 12                     | 100                    |
|                                                                 | Week24   | 158 | 80.01  | 16.04 | 84.00                  | 21                     | 100                    |
| MEM                                                             | Baseline | 159 | 82.25  | 14.58 | 87.00                  | 14                     | 99                     |
|                                                                 | Week12   | 150 | 81.18  | 14.89 | 86.00                  | 21                     | 100                    |
|                                                                 | Week24   | 151 | 80.68  | 16.28 | 86.00                  | 19                     | 98                     |
| DRAFT10158ETSIB0218APR2011:13:46:351001/175-TFL/SADBui1dNumberS |          |     |        |       |                        |                        |                        |

## 5) Study MEM-MD-22

This  was  a  24-week,  randomised,  double-blind,  placebo-controlled,  fixed-dose  study  evaluating  the effectiveness of memantine versus placebo with regard to behavioral symptoms, functional capabilities and overall quality of life in nursing home patients with moderate to severe AD.

## Method

## Inclusion criteria

Patients were aged ≥ 65 years, with a primary diagnosis of probable AD, a baseline MMSE score ≥ 5 and ≤ 18, and, if available, a CT or MRI performed prior to screening, confirming the diagnosis of probable AD. The patients were allowed to be on AChEI treatment prior to study start.

## Outcomes/endpoints

No primary or secondary efficacy analyses were pre-specified. Analyses were performed on a number of  Minimum  Data  Set  (MDS;  a  standardised  set  of  items,  used  to  assess  nursing  home  residents, addresses the residents' cognitive, behavioural, functional, and medical status) and non-MDS variables (NPI-nursing home or NPI-NH , CMAI, BGP, PANSS-EC, Multidimensional Observation Scale for Elderly Subjects  (MOSES)  -  Withdrawal  Behaviour  subscale,  and  AD  Cooperative  Study  -  Clinical  Global

<div style=\"page-break-after: always\"></div>

Impression of Change or ADCS-CGIC) assessed at each visit, based on the ITT population and using the  LOCF  and  OC  approaches.  The  analyses  were  two-way  analyses  of  covariance  (ANCOVA)  of memantine  versus  placebo  at  the  5%  level  of  significance.  A  total  sample  size  of  250  randomized patients was used for this study. The sample size was based upon clinical considerations judged to be reasonable for the exploratory objectives of this study.

## Results

A total of 263 patients were included in the ITT population: 132 in the memantine group and 131 in the  placebo  group.  A  total  of  96  patients  were  on  concurrent  treatment  with  donepezil  during  the study:  49  (37%,  APTS)  in  the  memantine  group  and  47  (36%)  in  the  placebo  group.  The  mean baseline scores for the non-MDS effectiveness variables were comparable between the two treatment groups.  A  total  of  58  patients  (22%,  APTS)  withdrew  from  the  study:  29  (22%)  in  the  memantine group and 29 (22%) in the placebo group.

At Week 24, there were improvements in both treatment groups in the non-MDS as well as the MDS effectiveness  variables.  There  were  no  statistically  significant  differences  between  the  treatment groups in any of the variables measured.

Results are presented in Table 14.

Table 14

Table 11.4.1.1-1. LeastSquareMeanChangeFromBaselineinnon-MDSEffectivenessVariable Total Scores at Week 24 (LOCF)-ITT Population

|           | LS Mean (SE)      | LS Mean (SE)        | LS Mean Difference (95% CI)   | p-Value   |
|-----------|-------------------|---------------------|-------------------------------|-----------|
|           | Placebo (N = 131) | Memantine (N = 132) | (Memantine-Placebo)           |           |
| NPI-NH    | -4.1 (1.3)        | -2.7 (1.3)          | 1.4 [-1.7, 4.5]               | 0.370     |
| CMAI      | -1.6 (1.1)        | -3.0 (1.1)          | -1.4 [-4.0, 1.2]              | 0.290     |
| BGP       | 1.6 (0.7)         | 0.9 (0.7)           | -0.7 [-2.3, 0.9]              | 0.381     |
| PANSS-EC  | -0.8 (0.5)        | -0.8 (0.5)          | -0.0 [-1.1, 1.1]              | 0.986     |
| MOSES     | 1.0 (0.4)         | 0.3 (0.4)           | -0.7 [-1.8, 0.3]              | 0.155     |
| ADCS-CGIC | 3.8 (0.14)        | 3.6 (0.14)          | -0.1 [-0.5, 0.2]              | 0.445     |

A negative change indicates improvement from baseline.

ADCS-CGIC is the change score.

CI = confidence interval; ITT = intent to treat; LOCF = last observation carried forward; LS = least square;.MDS =minimum data set

Cross-reference: Table 14.4.1.1A,14.4.1.2A,14.4.1.3A,14.4.1.4A,14.4.1.5A, and 14.4.1.6C.

## 6) Study MEM-MD-71

This  was  a  12-week,  randomised,  double-blind,  placebo-controlled,  fixed-dose  study  evaluating  the effect of memantine versus placebo on functional communication in patients with moderate AD.

## Method

## Inclusion criteria

The patients were outpatients, aged ≥ 50 years, with a primary diagnosis of probable AD, a baseline MMSE score ≥ 10 and ≤ 19, a baseline HIS score ≤ 4, and a CT or MRI performed ≤ 12 months prior to screening,  confirming  the  diagnosis  of  probable  AD.  The  patients  were  allowed  to  be  on  AChEI

<div style=\"page-break-after: always\"></div>

treatment prior to study start, provided the dose had been stable for ≥ 3months, and remained fixed for the duration of the study.

## Outcomes/endpoints

The primary efficacy analysis was the mean  change from baseline in Functional Linguistic Communication Inventory (FLCI) total score at Week 12, based on the ITT population and using the LOCF approach. The analysis was a two-way ANCOVA of memantine versus placebo at the 5% level of significance.  The  secondary  efficacy  analysis  was  based  on  the  American  Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA-FACS) score.

## Results

A total of 257 patients were included in the ITT population: 133 in the memantine group and 124 in the  placebo  group.  A  total  of  83  patients  were  on  concurrent  treatment  with  donepezil  during  the study:  44  (33%,  APTS)  in  the  memantine  group  and  39  (30%)  in  the  placebo  group.  The  mean baseline  FLCI  score  was  approximately  68  in  both  treatment  groups.  A  total  of  14  patients  (5.3%, APTS) withdrew from the study: 5 (3.7%) in the memantine group and 9 (7.0%) in the placebo group.

The mean change from baseline in FLCI total score at Week 12 (see Table 15) was numerically higher in  the  memantine  group  than  in  the  placebo  group,  indicating  a  trend  towards  better  response  in favour of memantine treatment; the difference was not statistically significant.

Table 15

Panel 10 Change from Baseline in FLCI Total Score at Week 12 (LOCF, OC, and MMRM) - Study MEM-MD-71 (ITT Population)

|                         | PBOa                | PBOa   | PBOa           | MEMa                                       | MEMa   | MEMa         |                             |                |
|-------------------------|---------------------|--------|----------------|--------------------------------------------|--------|--------------|-----------------------------|----------------|
|                         | Baseline Score (SE) | n      | LS Mean (SE)   | Baseline Score (SE)                        |        | LS Mean (SE) | LS Mean Difference (95% CI) | ANCOVA p-value |
| Primary Analysis (LOCF) |                     |        |                | (90) 40 911 (460) 499 (690) 90- 71 (01)849 |        |              | 1.3 (-0.1; 2.8)             | 0.070          |
| SensitivityAnalyses     |                     |        |                |                                            |        |              |                             |                |
| OC                      |                     |        | 119-0.3 (0.59) |                                            | 129    | 0.6 (0.56)   | 1.0 (-0.5; 2.4)             | 0.184          |
| MMRM                    |                     | 119    | 0.1 (0.54)     |                                            | 129    | 1.3 (0.52)   | 1.2 (-0.2; 2.7)             | 0.097          |

aIncludes monotherapy and concurrent treatment with an AChEI

## 7) Study 10112

This  was  a  52-week,  randomised,  double-blind,  placebo-controlled,  fixed-dose  study  evaluating  the effects of memantine on the rate of total brain atrophy in patients with probable moderate Alzheimer's disease over the course of treatment, using MRI technology.

## Method

## Inclusion criteria

The patients were outpatients, aged ≥ 50 years, with a primary diagnosis of probable AD, a baseline MMSE score ≥ 12 and ≤ 20, a HIS score ≤ 4 at screening and baseline, and an MRI performed prior to screening,  confirming  the  diagnosis  of  probable  AD.  The  patients  were  allowed  to  be  on  AChEI treatment prior to study start, provided the treatment had been ongoing for &gt;6months, at a stable dose for &gt;3months, and remained fixed for the duration of the study.

## Outcomes/endpoints

The primary efficacy analysis was the direct change in total brain volume (TBV), as measured using the brain boundary shift integral (BBSI), at Week 52, based on the FAS-MRI and using the OC approach.

<div style=\"page-break-after: always\"></div>

The  analysis  was  based  on  a  linear  mixed  model  relating  direct  change  in  TBV  to  time  and  its interaction  with  treatment  group.  This  model  also  included  a  time-by-AChEI  group  interaction  as  a fixed effect. The secondary efficacy analyses included the change in hippocampal volume atrophy rate, effects  of  memantine  on  cognitive  and  behavioural  outcomes,  and  correlation  between  TBV  atrophy rate and clinical outcomes.

## Results

A total of 275 patients were included in the FAS: 133 in the memantine group and 142 in the placebo group. A total of 123 patients were on concurrent treatment with donepezil during the study: 57 (43%, APTS) in the memantine group and 65 (45%) in the placebo group. There were no clinically significant differences  in  baseline  characteristics  between  the  treatment  groups.  A  total  of  60  patients  (22%, APTS)  withdrew  from  the  study:  30  (23%)  in  the  memantine  group  and  30  (21%)  in  the  placebo group. The primary analysis showed no statistically significant differences between the memantine and placebo groups in total brain atrophy rates.

## 2.5.3. Analysis performed across trials (pooled analyses and metaanalysis)

## Efficacy of the combination over donepezil

Following  CHMP  request  to  further  substantiate  the  efficacy  of  the  combination,  the  applicant conducted a number of meta-analyses. Results are presented in Figures 6 and 7.

Figure 6: Summary of meta-analysis (2 studies, target population) with standardised mean differences for each of the three main Alzheimer's disease domains (cognition, global assessment, activities of daily living)

StandardizedMeanDifferenceEstimate;95%ConfidenceInterval Meta-analysesOutcome Two studies(MEM-MD-02 and MEM-MD-12); ITT, target population*

<!-- image -->

DPZ, donepezil; ITT, intention-to-treat; LOCF, last observation carried forward; MEM, memantine; OC, observed case; PBO,placebo.

* Target population (patients with MMSE score of 10 to 19) treated with 20 mg memantine/10 mg donepezil [MEM/DPZ] per day compared with placebo/10 mg donepezil [PBO/DPZ] per day.

Figure 7: Summary of meta-analyses (4 studies) with standardised mean differences for

<div style=\"page-break-after: always\"></div>

each of the three main Alzheimer's disease domains (cognition, global assessment, activities of daily living)

Standardized Mean Difference Estimate, 95% Confidence Interval Meta-analyses Outcome Four studies (MEM-MD-02, MEM-MD-12, MEM-MD-22, and 10158); ITT, target population*

DPZ, donepezil; ITT, intention-to-treat; LOCF, last observation carried forward; MEM, memantine; OC, observed case; PBO,placebo. * Target population (patients with MMSE score of 10 to 19) treated with 20 mg memantine/10 mg donepezil

<!-- image -->

[MEM/DPZ] per day compared with placebo/10 mg donepezil [PBO/DPZ] per day.

## 2.5.4. Ancillary analysis

In addition to the meta-analyses provided, the applicant submitted a non-responder analysis to further support the efficacy of the combination.  Results are presented in Figure 8.

<div style=\"page-break-after: always\"></div>

Figure 8 : Summary of Analyses on Marked Clinical Worsening ('Non-responder')

Odds Ratio Estimate; 95% Confidence Interval Meta-analysis Outcome; Triple \"non-responder\" analysis (marked clinical worseningt) including four studies (MEM-MD-02, MEM-MD-12, MEM-MD-22, and 10158); ITT, target population*

<!-- image -->

DPZ, donepezil; ITT, intention-to-treat; LOCF, last observation carried forward; MEM, memantine; OC, observed case; PBO,placebo.

* Target population (patients with MMSE score of 10 to 19) treated with 20 mg memantine/10 mg donepezil [MEM/DPZ] per day compared with placebo/10 mg donepezil [PBO/DPZ] per day.

† At study endpoint: marked clinical worsening in three Alzheimer's disease domains (cognition, global assessment and activities of daily living).

## 2.5.5. Clinical studies in special populations

No clinical studies in special populations have been performed with the combination (memantine/donepezil).

## 2.5.6. Supportive studies

The  applicant  submitted  a  bibliographical  analysis  to  claim  a  widespread  use  of  the  combination (memantine/donepezil) and support the reduced amount of clinical data submitted in this application. This  analysis  consisted  of  available  treatment  guidelines/expert  panel  recommendations,  published studies  (including  clinical,  observational  and  market  research  data)  and  included  a  review  of epidemiological, market research and prescription data.

In  addition,  following  the  CHMP  reference  to  a  recent  publication  from  Howard  et  al.  (2012),  the applicant presented results of this study (DOMINO) as supportive of efficacy of the combination.

<div style=\"page-break-after: always\"></div>

## 2.5.6.1. Treatment guidelines/expert panel recommendations

## Treatment guidelines

These are presented in Table 16.

## Table 16

| Country        | Guidelines for combination therapy of memantine and AChEIs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Austria        | The combination therapy of memantine and AChEIs is desirable for patients with severe or moderate AD (MMSE benchmark 5-14). In a randomised study by Tariot et al., 2004 the combination of memantine and donepezil proved to be superior to monotherapy with donepezil. Furthermore open studies have shown that combination therapy with rivastigmine and memantine are also more effective than monotherapy alone. Another study reports the positive effect of combination therapy compared with the use of AChEIs alone over a period of several years.                                                                 |
| Czech Republic | To improve the effect of AChEIs, memantine can be added - this combination, although expensive, is rational and evidencebased (e.g. the study of the Cummings et al., 2006), and is recommended in other guidelines for example the Italian Psychogeriatric Association guidelines, which are taken as a model for the therapy of dementia in the EU countries (Caltagirone et al., 2005). In the moderate stage of AD, AChEIs are still the leading pharmacological therapy, but it is possible to add memantine. Even in patients who had not taken AChEIs previously, it is possible to prescribe combination therapy, if |
| Denmark        | Combination therapy may be relevant in patients treated with ACHEIs with AD progressing to the moderate stage with a MMSE score of 10-14. Patients treated with ACHEIs in the moderate stage can be treated with a combination of an AChEI and Ebixa (memantine). When the disease has progressed to the severe stage treatment with Ebixa (memantine) as monotherapy is continued.                                                                                                                                                                                                                                          |
| Finland        | Use of combination therapy (memantine &AChEI) in moderate and severe AD might delay nursing home placement. Memantine combined to donepezil might decrease behavioral disturbances in some of moderate and severe AD patients. Memantine combined to AChEI in mild AD doesn't give any additional benefits.                                                                                                                                                                                                                                                                                                                  |
| France         | Combination therapy (AChEI and memantine) was compared to monotherapy with AChEIs in 2 clinical trials with contradictory results. Based on presently available data, there are no arguments to recommend combination therapy.                                                                                                                                                                                                                                                                                                                                                                                               |
| Germany        | An add-on treatment with memantine in patients treated with donepezil is superior to monotherapy with donepezil in severe Alzheimer's dementia (MMSE 5-9) - recommendation: can be done. An add-on treatment with memantine in patients with mild to moderate AD (MMSE 15-22) already treated with AChEIs has shown no superiority to a monotherapy with AChEIs. The combination is not recommended. For an add-on treatment with memantine in patients with moderately-severe AD (MMSE 10- 14) already treated with AChEIs there is no convincing evidence. No recommendation can be given.                                 |
| Hungary        | Memantine therapy is indicated in severe AD (MMSE < 10) or in moderate AD (MMSE 18-11), either as an adjuvant therapy to AChEIs or, in case of inefficacy or intolerability of AChEIs, as a monotherapy. According to the preliminary results add on therapy of memantine in combination with an AChEI could be beneficial.                                                                                                                                                                                                                                                                                                  |
| Iceland        | No reference to combination treatment within the guidelines for dementia or AD.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Italy          | Memantine is effective as an adjunct to donepezil in patients with moderate to severe AD.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Netherlands    | No reference to combination treatment within the guidelines for dementia or AD.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Poland         | Combination therapy (AChEIs and memantine) is one of the therapeutic options for treating AD.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Romania        | For patients who progress from mild to moderate-stage AD (MMSE 14-20) memantine can be added (10-20 mg daily dose) to AChEI treatment, especially when rapid progression occurs. Memantine can be used in this situation as monotherapy, or as combination therapy. Patients with moderate-stage AD (MMSE 10-14) should be treated with a combination of AChEI and memantine.                                                                                                                                                                                                                                                |
| Slovenia       | No reference to combination treatment within the guidelines for dementia or AD.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Spain          | In patients already receiving an AChEI, it is possible to add memantine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Sweden         | For patients with moderate to severe AD -adding memantine to treatment with an AChEI (donepezil) was recommended at level 6 out of 10 (with 1 being the strongest recommendation).                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| UK             | Combination treatment with memantine and AChEIs cannot be recommended because there is a lack of evidence of additional clinical efficacy compared with monotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

EFNS

The benefits of adding memantine to AChEIs are not clear, an early study of adding memantine to donepezil was positive, but a recent study of over 400 subjects which added the drug or placebo to those stable on any of the three AChEIs showed no evidence of benefit in either cognitive or non-cognitive symptoms. Further studies are needed before clear recommendations can be made about the benefits of adding memantine to AChEIs.

No guidelines relating to the treatment of dementia or AD in Belgium, Bulgaria, Cyprus, Estonia, Greece, Ireland, Latvia, Lithuania, Luxembourg, Malta, Norway, Portugal, Slovakia.

## Expert-panel recommendations

Three additional guidelines that have been developed and published to assist health care professionals in the effective pharmacologic management of patients with AD, in order to optimise patient outcomes were identified from the literature search:

-  The  US  Alzheimer's  Disease  Management  Council  Clinical  Consensus  Panel  (ADMC,  2004).  This algorithm indicated that memantine should be added when no stabilization or reduction in the rate of cognitive and functional decline is observed during AChEI monotherapy, despite dose optimization and switching strategies.
- The US Alzheimer's Drug Discovery Foundation (ADDF) panel-approved recommendations stated that for patients who progress from mild to moderate AD, memantine should be added to therapy with an AChEI.
- An educational supplement for Nurse Practitioners: the authors concluded that memantine and AChEI combinations appeared to be a well-tolerated, effective treatment strategy.

## 2.5.6.2. Published studies

Available  literature  data  related  to  clinical  trials  and  post-hoc  analyses  of  memantine  and  donepezil combination therapy and observational studies for combination therapy with memantine and AChEIs are presented in Table 17.

## Clinical trial data and post-hoc analyses

Table 17. Clinical trial data identified from the literature search

| Author andDate                                  | Title and overview of paper                                                                                                                                                                                                                                    |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Porsteinssonetal.,2008                          | Memantine treatment in patients with mild to moderate AD already receiving anAChEI;Arandomized,double-blind,placebo-controlledtrial.                                                                                                                           |
| Tariotetal.,2004                                | Memantinetreatment inpatientswithmoderatetosevereADalready receiving donepezil:A randomized controlled trial.                                                                                                                                                  |
| Post-hocanalysesofTariotetal.,2004clinicaltrial | Post-hocanalysesofTariotetal.,2004clinicaltrial                                                                                                                                                                                                                |
| Cummings et al., 2006                           | Title: Behaviour effects of memantine in AD patients receiving donepezil treatment.                                                                                                                                                                            |
| Cummings et al., 2006                           | Results:Patients treatedwith combined therapy ofmemantine and donepezil hadsignificantlylowerNPItotalscores than patientstreatedwithplacebo (donepezil only).Combination treatment reduced agitation/aggression, initability and appetite/eating disturbances. |
| Feldman et al., 2006                            | Title:Activities ofDaily Living in moderate to severe AD: An analysis ofthe treatment effects of memantine inpatientsreceiving stabledonepezil treatment.                                                                                                      |
| Feldman et al., 2006                            | Results:Combination therapy ofmemantine and donepezilreduced the overall functional decline in moderate to severe AD patients compared with donepezil treatment alone.                                                                                         |
| Schmitt et al., 2006                            | Title: Cognitive response to memantine in moderate to severe ADpatients alreadyreceiving donepezil.                                                                                                                                                            |
| Schmitt et al., 2006                            | Results:Statisticallygreatereffectsofcombinationtherapyoverdonepezil alonewereseen inmemory,language andpraxis.                                                                                                                                                |
| van Dyck et al., 2006                           | Title:AresponderanalysisofmemantinetreatmentinpatientswithAD maintained on donepezil.                                                                                                                                                                          |
| van Dyck et al., 2006                           | Results:Memantineproducedbothimprovement andstabilisation of symptoms, across mmltiple outcomes using ADCS-ADL19, SIB, CIBIC-Plus and NPI.                                                                                                                     |

<div style=\"page-break-after: always\"></div>

## Observational studies and clinical effectiveness studies

Two  studies  conducted  in  a  clinical  practice  setting  specifically  presented  results  in  regard  to memantine and AChEI combination therapy:

-  Atri  et  al.  (2008)  conducted  a  long-term,  real-world  clinical  effectiveness  study  that  enrolled  a prospective cohort of patients from a Memory Disorders Unit with a diagnosis of AD. Patients received either memantine plus an AChEI (n=116), an AChEI alone (n=122) or no treatment (n=144). Results showed that patients receiving combination therapy with memantine and an AChEI had significantly lower mean annualised rates of deterioration in two measures, the Blessed Dementia Scale (BDS) and Weintraub Activities of Daily Living Scale (ADL). These cognitive and functional benefits increased with time on treatment and were sustained for years.

- A recent (Lopez et al., 2009) retrospective, observational study in 943 patients with AD, with at least one year of follow-up data, showed that time to nursing home admission was significantly delayed in patients  receiving  memantine  and AChEI combination therapy compared with those receiving AChEI monotherapy.

## Market research studies

Two market research surveys (InforMed Insight and Adelphi Real World Disease Specific Programme) were conducted in 2010 to address when and why physicians prescribe combination treatment:

-  InforMed  Insight  conducted  75-minute  interviews  with  80  neurologists  and  geriatricians  in  5 European countries. When physicians were asked for their criteria for initiating combination treatment, they  stated  that  although  MMSE  scores  were  taken  into  account,  they  had  less  relevance  in  the moderate stage than in the  milder  stages  of  the  disease.  For  them,  the  main  reasons  for  initiating combination treatment were  progression of the disease to the moderate/severe  stage, clear degradation of behavioural symptoms, or a request from the patient's family/carer because of concern regarding  patient  decline.  When  asked  why  they  prescribed  combination  treatment,  the  physicians stated  that  the  reason  was  based  both  on  the  published  evidence  and  on  their  own  and  their colleagues' clinical experiences. For them, the main treatment goals with combination treatment were to stabilise the patient, in terms of slowing the progression and preserving the function of the patient as much as possible, and to lessen the impact of the condition on the carers'/families' quality of life, especially in relation to behavioural aspects of the disease.

- The Adelphi Real World Disease Specific Programme (ARW DSP) collected prospective, quantitative and qualitative data from 552 general practitioners and specialists in 5 European countries. Physicians stated that the four main reasons for prescribing combination treatment were, in order of importance: slowing  disease  progression,  delaying  entry  into  care/nursing  home,  improving  short-term  memory, and improving/maintaining concentration/attention. A further reason for choosing combination treatment over AChEI monotherapy was the reduction in anxiety and reduction in irritability.

Data  of  a  Decision  Base  market  research  survey  were  also  provided.  Results  showed  that  the neurologists regarded combination treatment to be the most efficacious therapeutic approach available to  treat  moderate  to  severe  AD.  The  arguments  included  effects  on  cognitive  decline,  function, behaviour, and global impression of change, all of which represent the clinical outcomes often used in studies of treatments for AD.

<div style=\"page-break-after: always\"></div>

## 2.5.6.3. Review on epidemiological, market research and prescription data

## Epidemiological data

An  overview  of  epidemiological  studies  including  patients  on  memantine  and  AChEI  combination treatment was provided including data from the following European countries: France, Spain, and the Czech Republic, Germany, Greece, Austria.

According  to  the  applicant,  trends  for  the  global  prevalence  of  memantine/donepezil  combination treatment  were  globally  similar  to  those  observed  for  treatment  with  memantine  and  any  AChEIs. Highest rates of this combination therapy were observed in France (45-47%), Spain (16- 38%); and the Czech Republic (9%). These rates were reduced relative to the overall prevalence of memantine/AChEI treatment as this category included patients treated with various other AChEIs in addition to donepezil.  Based on this analysis, a calculation of the prevalence of donepezil prescriptions could be made up between 42% and 57% of total AChEI/memantine prescriptions. The prevalence of memantine/donepezil treatment was comparable between the overall AD population and the targeted indication (moderate to moderately severe AD). Within this subset of patients, donepezil was estimated to account for about half of total AChEI usage, being responsible for between 36% and 59% of AChEI prescriptions.

## Market Research data

## ARW-DSP

The  ARW  DSP  was  conducted  in  2004,  2006,  2008  and  2010,  in  five  European  countries:  United Kingdom, France, Germany, Spain and Italy. The study was conducted every 2 years (referred to as a 'wave'). Approximately 90 to 120 physicians (both general practitioners (GPs) and specialists including psychogeriatricians,  geriatricians,  psychiatrists,  neuropsychiatrists,  and  neurologists)  were  recruited for each wave of the study.  Physicians were asked to recruit their next 10 consecutive patients seen in consultation  who  met  the  following  inclusion  criteria:  aged  over  50  years  and  with  symptoms  of cognitive impairment.  Patients with AD formed a subset of this sample.

Overall results are presented in Figures 9 and 10.

## Figure 9

<div style=\"page-break-after: always\"></div>

## Figure 10

<!-- image -->

## Cegedim Customer Information Online Tracker (CCI-OT)

Cegedim Customer Information carried out an online survey in May 2010 which targeted physicians (neurologists, psychiatrists, geriatricians, internal medicine and GPs) from nine countries in order to track sales force and marketing effectiveness. Recruited physicians (n = 645) completed a 10 minute online questionnaire which addressed their perceptions of different treatments available for AD and their prescription behaviour/habits (Figure 11).

## Figure 11

with any AChEI. Data from 2010 (ARIW' DSP).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Physicians surveyed in the CCI-OT were also asked about the proportion of prescriptions that combined therapy would account for, out of all prescriptions for patients with moderate stage AD. Results varied by individual countries from 3% to 26%; however similar patterns in terms of which countries were typically reported to be either higher or lower prescribers of combination therapy, were recorded (see Figure 12).

<div style=\"page-break-after: always\"></div>

## Figure 12

<!-- image -->

## c) Decision Resources Physician Survey

Decision Resources conducted market research during September 2009 in France (FR), Germany (DE), Italy (IT), Spain (ES) and United Kingdom (UK). A total of 256 neurologists (FR: 52; DE: 54; IT, ES, UK: 50) completed the survey over the internet. The survey was perception-based and assessed physician opinions in relation to different treatments available for AD.

Physicians were asked what proportion of their moderate stage patients would be receiving an AChEI alone versus an AChEI in combination with memantine. Responses ranged from 18% to 41%.

Data from ARW DSP showed the reported proportion of moderate to moderately-severe AD patients receiving memantine and an AChEI as combined therapy (see Figure 13).

Figure 13

<!-- image -->

<div style=\"page-break-after: always\"></div>

## d) Observational retrospective market research study

Between December 2010 and January 2011, an observational market research study was conducted using retrospective analysis of the medical records of patients with AD. The primary objective of this study was to document the extent of use of combination therapy with donepezil in patients prescribed memantine across 15 countries in the EU (Austria, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Spain, Sweden, United Kingdom).

Overall, 502 specialists (neurologists, geriatricians and psychiatrists) were recruited, who provided data for a total of 5,020 patients. The specialists agreed to retrieve patient records for the last 10 patients with AD that they had seen and to complete a questionnaire about themselves and their treatment practices. Results were summarised as follows:

-  In this population, patients with moderate to moderately severe AD represented 51.1% of all patients and 55.4% of patients treated with AD drugs (treated patients).
-  55.2% of the patients who were prescribed memantine, and 58.4% of the patients with moderate to moderately severe AD who were prescribed memantine, received combination therapy with an AChEI.
-  The AChEI most commonly used in combination with memantine was donepezil, which was used in 49.1% of all patients prescribed combination therapy and in 27.1% of all patients prescribed memantine.
-  Donepezil was co-prescribed in 29.9% of all patients with moderate to moderately severe AD who were prescribed memantine.
-  Of those patients receiving combination therapy with memantine plus donepezil: 52.8% were prescribed 20 mg of memantine; 83.4% were prescribed 10 mg of donepezil; 46.7% were prescribed 20 mg of memantine and 10 mg of donepezil.

## Prescription Data

A report on prescription data was submitted. The objective was to investigate the extent of the coprescription of memantine with AChEIs in general and, with donepezil, specifically, across a number of European countries. Results were drawn from 2 databases and are presented below.

## a) IMS-Prescribing Insights Database (IMS-PID)

The IMS-PID was used to provide prescription estimates of memantine in combination with an AChEI for France, Germany, Italy, Spain and the United Kingdom (UK) from the period of April 2008 to April 2009. Results are presented in Figures 14 and 15.

<div style=\"page-break-after: always\"></div>

## Figure 14

## Figure 15

Figure 2. Proportions of memantine-treated patients receiving mono- or combination therapy with any AChEI in 5 European countries (IMS-PID 2008/2009)

<!-- image -->

Figure 5. Proportions of all memantine-treated patients receiving mono- or combination therapy with donepezil versus other AChEIs (IMS-PID 2008/2009)

<!-- image -->

## b) Cegedim Strategic Data-Longitudinal Patient Database (CSD-LPD)

The data in the CSD-LPD were considered observational, in that each interaction between a physician and  patient  was  captured.  The  CSD-LPD  contains  data  for  France,  Germany,  Italy,  Spain,  UK  and Belgium. Data from July 2009 to July 2010 were analysed. Detailed of the results are presented in Figures 16 and 17.

<div style=\"page-break-after: always\"></div>

Figure 16 Figure 3.Proportions of memantine-treatedpatients receivingmono-or combination therapywith any AChEIin 6 European countries (CSD-LPD 2009/2010)

Figure 17

<!-- image -->

Figure6.Proportionsofmemantine-treatedpatientsreceivingmono-orcombinationtherapywith donepezil ver'sus other AChEIs (CSD-LPD 2009/2010)

<!-- image -->

## 2.5.6.4. Publication from Howard et al. - DOMINO study

The  DOMINO  study  included  AD  patients  who  were  already  treated  with  donepezil.  Patients  were randomly  assigned  to  continue  donepezil,  discontinue  donepezil,  discontinue  donepezil  and  start memantine, or continue donepezil and start memantine.

The 2 primary efficacy parameters were based on the standardised MMSE (SMMSE) score and the Bristol Activities of Daily Living Scale (BALDS). Results are presented in Figure 18.

<div style=\"page-break-after: always\"></div>

## Figure 18

Panel5:1 Mean Scores on the Standardized Mini-lMental-State Exanination and the Bristol Activities of Daily Living Scale; Panel taken from the publication Howard et al. [Howard 2012]

<!-- image -->

s ofDaily LivingScale(BADLS),According toVisit Week and Treatment Group.

For easier visualisation, colours were added to the lines indicating the individual treatment groups.

According to the applicant, the treatment effects obtained in the active treatment groups (combination therapy  and  monotherapy  treatment  arms)  can  be  easily  distinguished  from  the  placebo  group. Numerically,  the  best  treatment  effects  for  both  primary  efficacy  parameters  (SMMSE  and  BADLS) were  consistently  achieved  in  the  combination  treatment  group.  This  was  most  prominent  after  30 weeks of treatment and was still present at the end of the study (Week 52). At Week 52 approximately 60%  of  the  patients  initially  included  in  the  study  were  no  longer  participating,  leading  to  a substantially reduced statistical power of the evaluations at Week 52. Furthermore, due to the different discontinuation rates of patients per treatment group, the size of treatment groups at Week 52 was no longer proportionate.

## Efficacy of the combination over memantine alone

Following the CHMP reference to a recent publication from Howard et al. (2012) on the DOMINO study, the applicant further discussed the efficacy of the combination versus memantine. Of note, the same group  of  authors  also  previously  published  a  paper  on  the  Minimally  Clinically  Important  Difference (MCID) for both primary efficacy parameters [Howard 2011]. For SMMSE score a 1.4 point difference was  considered,  whereas  for  BADLS  score,  a  difference  of  at  least  3.5  was  found  to  be  clinically important. According to the applicant, the results showed that combination treatment was superior to memantine monotherapy and, for this comparison, the pre-defined MCID was exceeded at Week 30 for both primary efficacy parameters SMMSE (MCID ≥ 1.4) and BADLS (MCID ≥ 3.5). Results at week 30 are presented in Table 18.

<div style=\"page-break-after: always\"></div>

Table 18

Panel 6:Treatnent Differences in SMMSE and BADLS Changes at Week 30

|                                                    | MMSE        | MMSE                                  | BADLS       | BADLS                                  |
|----------------------------------------------------|-------------|---------------------------------------|-------------|----------------------------------------|
| Comparison between the treatment groups at Week 30 | Mean values | Differencebetween thetreatment groups | Mean values | Difference between the treatmentgroups |
| Combination compared with Memantine                | 8.4; 6.1    | 2.3                                   | 30.7; 34.5  | -3.8                                   |

The numbers above are derived form the Figure 3 (Panel 5 in this document) in the article Howard et al, 2012 (DOMINO study).

## 2.5.7. Discussion on clinical efficacy

The clinical efficacy data provided considered the CHMP Guideline on the Clinical Development of Fixed Medicinal Products (CPMP/EWP/240/95, Rev 1).

## Clinical Efficacy

Study MEM-MD-02 showed that patients on memantine/donepezil treatment achieved better scores in cognitive scales and in daily living activities than patients continuing on donepezil at 24 weeks. In this study, the two primary endpoints were the changes from baseline at week 24 of the SIB total score and the ADCS-ADL modified score, and the secondary endpoints included the CIBIC- plus score. At week 24 (LOCF), the mean changes were : 2.5 and 0.9 for SIB total score and -3.4 and 2.0 for  ADCSADL modified score for the placebo/donepezil and memantine/donepezil groups, respectively (BIS total score: p&lt;0.001; ADCS-ADL modified score: p=0.028). For the CIBIC-plus score, the mean value was 4.66  for  the  placebo/donepezil  group  as  compared  to  4.41  for  the  memantine/donepezil  group (p=0.027). Results from LOCF and OC analyses were consistent for these endpoints.

However, the contribution to the effect from memantine alone cannot be determined due to the lack of memantine monotherapy control arm. In addition, study MEM-MD-02 was not specifically designed for the proposed fixed-association dose. Hence, the CHMP considered that the study design for MEM-MD02 did not allow to confirm the efficacy of the fixed combination in the intended population.

There were two other 24 week duration studies (MEM-MD-12, 10158). These studies recruited a low proportion of patients on donepezil and failed on their primary analysis to show statistical difference of the memantine/AchEI group compared to the placebo/AchEI group.

Other studies did not bring additional evidence, as none of them met their main efficacy endpoints, and as they varied in their design.

No specific dose-finding studies have been performed hence the optimum doses for the combination is currently unknown. The applicant justified this lack of studies based on the proposed indication for the fixed combination (substitution indication in patients already at stable doses of memantine 20 mg and donepezil 10 mg). Taking into account the continuous need for dose titration in AD patients, the CHMP was of the opinion that in accordance with the CHMP Guideline on the Clinical Development of Fixed Medicinal Products (CPMP/EWP/240/95, Rev 1) referred previously, dose response of the combination should  have  been  investigated  to  determine  to  what  extent  each  active  component  independently contributes to the efficacy and safety of the combination (see section 2.6).

## Additional efficacy analyses

Efficacy of the combination over donepezil alone

<div style=\"page-break-after: always\"></div>

Two meta-analyses were performed in  the  targeted  population  (moderate  to  moderately  severe  AD defined as patients with MMSE 10 to 19) treated with 20 mg memantine/10 mg donepezil (per day).

In  the  second  meta-analysis  including  the  largest  number  of  trials,  a  total  of  527  patients  were included  and  represented  a  subpopulation  (from  23.4%  to  48.6%)  of  the  total  patients  originally studied.  According  to  the  applicant,  results  in  the  three  main  efficacy  domains  (cognition,  global assessment,  and  activities  of  daily  living)  were  consistently  in  favour  of  the  combination  treatment compared  with  donepezil monotherapy  in the first analysis. In addition, patients receiving donepezil/memantine treatment performed significantly better than patients treated with placebo/donepezil on cognition scales (LOCF) and global assessment (OC and LOCF) at Week 24, with a  trend  favouring  the  memantine/donepezil  group  in  the  LOCF  analysis  (p=0.09)  for  the  domain activities of daily living.

A non-responder analysis was also performed in the targeted population to evaluate the efficacy of the combination on the reduction of clinical worsening.  Non-responders were defined as a worsening in cognition (by at least 4 points in ADAS-cog, 5 points in SIB or 1 point in BGP-cog and any worsening in global  assessment  (ADCS-CGI-C/CIBIC-Plus)  and  any  worsening  in  activities  of  daily  living  (ADL23, ADL19, BGP-care dependency) at study endpoint compared with baseline at week 24 . According to the applicant, statistical significant difference was observed for the donepezil/memantine group compared to placebo/donepezil group on the reduction of clinical worsening. Twice as many patients treated with placebo/donepezil  experienced  a  marked  clinical  worsening  in  the  three  domains  compared  with patients  treated  with  donepezil/memantine  (LOCF  16.08%  versus  8.53%,  and  OC  13.74%  versus 7.73%).

Although  these  analyses  seemed  to  suggest  an  additional  effect  of  memantine  when  compared  to donepezil  alone,  the  CHMP  was  of  the  opinion  that  these  results  could  only  be  considered  as exploratory due to several limitations in their designs (e.g. examination of subgroup of patients, post hoc nature of the analyses, different efficacy endpoints assessed in each trial).

## Efficacy of the combination over memantine alone

No additional analyses were initially provided by the applicant to address the concern over the lack of comparison  of  the  efficacy  of  the  combination  versus  memantine  group  on  the  basis  that  this application relates to a substitution indication.

However, during the evaluation, a recent publication from Howard et al. (2012) evaluating different therapeutic strategies in patients with moderate to severe AD (DOMINO study) was identified by the CHMP.  In  this  study,  patients  already  treated  with  donepezil  were  randomly  assigned  to  continue donepezil,  discontinue  donepezil,  discontinue  donepezil  and  start  memantine,  or  continue  donepezil and  start  memantine.  After  52  weeks  of  follow-up  there  was  no  significant  benefit  of  adding memantine to donepezil with respect to scores on cognition (MMSE 0.8 points higher with memantine than with placebo; 95% CI, -0.1 to 1.6; p=0.07) or on the activities of daily living (BADLS 0.5 points lower with memantine than with placebo; 95% CI, -2.2 to 1.2; p= 0.57). From the CHMP viewpoint, these data reinforce the uncertainties over the efficacy of the combination and its place in AD therapy. These uncertainties further question its  use  as  substitution  indication  in  the  treatment  of  AD  in  the absence of robust data demonstrating the efficacy of the combination in the intended population.

According to the applicant, the treatment effects obtained in the active treatment groups (combination therapy  and  monotherapy  treatment  arms  can  be  easily  distinguished  from  the  placebo  group. Numerically,  the  best  treatment  effects  for  both  primary  efficacy  parameters  (SMMSE  and  BADLS) were  consistently  achieved  in  the  combination  treatment  group.  This  was  most  prominent  after  30 weeks of treatment and was still present at the end of the study (Week 52). Therefore, it was the applicant's opinion that the results obtained at Week 30 should be considered as a more reliable basis

<div style=\"page-break-after: always\"></div>

for  making  conclusions  regarding  combination  treatment  than  results  obtained  at  Week  52.  The acceptability  of  the  proposed  analysis  was  however  questioned  by  the  CHMP  due  to  several methodological limitations. Indeed, this was a post-hoc analysis with its inherent limitations but also in the absence of the numbers for the mean values, estimations were made by the applicant. In addition the time-point of week 30 was chosen arbitrarily without justification. The DOMINO study included a more  severe  population  (MMSE  5-13)  than  the  targeted  indication  applied  for  ie  moderate  to moderately severe AD (MMSE 10-19).

In  the  absence  of  robust  data  demonstrating  the  efficacy  of  the  combination  in  the  intended population, the CHMP considered these results of limited relevance. Moreover, the CHMP noted that the 60 % drop out rates at week 52 could also reflect the absence of a real temporal benefit in the use of the fixed combination in most patients that are on combination therapy since the patients did not stay on the highest dose of both memantine/donepezil for a long period, and that most likely a detitration of either component was required.

## Data on simultaneous use

Treatment  guideline/expert  panel  recommendations  on  management  of  AD  vary  across  European Union. Seventeen references to European guidelines have been provided. According to the Applicant, the majority of the guidelines acknowledged the combination use in the moderate stage of the disease. The CHMP however noted that 2 recent European publications ie 'NICE technology appraisal guidance 217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease' and 'EFNS Guidelines for the diagnosis and management of Alzheimer's disease, 2010' stated that the benefits  of  adding  memantine  to  AChE  inhibitors  were  not  clear  with  the  currently  available  data. Moreover, the conclusions of the NICE review were that 'combination treatment with memantine and AChE inhibitors could not be recommended because of lack of evidence of additional clinical efficacy compared with memantine monotherapy ' suggesting that the available data on simultaneous use are currently  insufficient  to  support  a  substitution  indication  for  a  fixed  combination  in  the  indication applied for (moderate to moderately severe AD).

Published  studies  related  to  6  clinical  trials  (including  MEM-MD-02  and  MEM-MD-12,  previously discussed) and 2 observational studies. Considering the lack of control arm including memantine alone in  the  clinical  trials  and  the  methodological  limitation  inherent  to  observational  design,  the  CHMP considered that no new relevant information could be retrieved from these publications.

Results from the epidemiological studies showed important differences in the use of the combination among the European countries. According to the applicant, these differences could be explained by the different reimbursement policy across the EU. However, the CHMP considered that these differences also reflected the general lack of consensus regarding the clinical use of the combination in the EU. Data  were  made  available  for  6  European  countries  only,  thus  not  allowing  a  generalisation  of  the findings  to  the  EU  population.  Market  research  and  prescription  data  also  revealed  considerable differences  in  estimates  of  the  use  and  prescription  of  memantine  in  combination  with  AChEIs (including donepezil) across the EU (see section 2.5.6.3).

In view the above, the CHMP considered that whilst the presented bibliographical analysis had some methodological limitations (e.g. retrospective access to the data, lack of randomization, limited number of  countries or patient population involved), memantine and AChEIs (mostly donepezil)  were being prescribed as a combination therapy for AD. However, their clinical use varied considerably across the EU. The differences could be explained by the limited efficacy of available treatments for the treatment of  AD,  the  lack  of  consensus  in  the  therapeutic  recommendations  in  force  in  each  country,  the differences in the financial supplies of medicines or in the local organization of health systems. These findings also indirectly correlated with the heterogeneity seen among available treatment

<div style=\"page-break-after: always\"></div>

guidelines/expert  panel  recommendations  previously  referred  to.  The  CHMP  was  therefore  of  the opinion  that  the  data  on  simultaneous  use  of  memantine  20  mg  and  donepezil  10  mg  across  the European Union were insufficient to support a substitution indication for the fixed combination in the treatment of moderate to moderately severe Alzheimer disease.

During  the  oral  explanation,  the  applicant  claimed  that  the  requirements  outlined  in  the  CHMP guideline on the clinical development of fixed medicinal product (CPMP/EWP/240/95) were met for this application, and reiterated their position on the widespread use of the combination being adequately established.  In  addition,  the  applicant  referred  to  the  DOMINO  study  and  the  additional  post-hoc analyses performed to further substantiate the efficacy of the combination in the intended population.

Having considered the oral explanation given by the applicant, the CHMP maintained its position that the efficacy of the combination has not been sufficiently demonstrated since the presented data did not change the overall efficacy discussion.

## 2.5.8. Conclusions on the clinical efficacy

The CHMP concluded the following:

-  The  efficacy  of  the  combination  (memantine  20  mg/donepezil  10  mg)  versus  the  components administered individually in the treatment of moderate to moderately severe Alzheimer's disease has not been sufficiently demonstrated

- The data on simultaneous use of memantine 20 mg and donepezil 10 mg across the European Union are  insufficient  to  support  a  substitution  indication  for  the  fixed  combination  in  the  treatment  of moderate to moderately severe Alzheimer's disease.

## 2.6. Clinical safety

From the safety database including 24 clinical studies, 5 pools of studies were made according to the design of the studies as follows:  1) 24-week, Double-blind, Placebo-controlled Studies (MEM-MD-02, MEM-MD-  12,  MEM-MD-22,  and  10158)  or  pool  1;  2)  12-week,  Double-blind,  Placebo-controlled Studies Pool (MEM-MD-23 and MEM-MD-71) or pool 2; 3) 24-28-week, Open-label Extension (OLEX1) Studies  (MEM-MD-03AB,  MEM-MD-12A,  and  10252)  or  pool  3;  4)  52-week,  Open-label  Extension (OLEX2) Studies (MEM-MD-03C and MEMMD-12B) or pool 4;  5) 12-week, Open-label Studies (MRZ 0608 and MRZ 3001) or pool 5.

Pools  3,  4  and  5  included  extension  studies  that  were  not  submitted  as  part  of  this  application  to support the efficacy.

## 2.6.1. Patient exposure

A total of 1626 patients received memantine/donepezil (MEM/DPZ) and accrued 1522.7 patient years of exposure to memantine in combination with donepezil during the studies. Overall, nearly 75% of the patients  received  10  mg/day  donepezil,  24%  received  5  mg/day  donepezil,  and  less  than  1.5% received another dose.

Twenty % of the overall patients had severe AD (MMSE&lt;10), two-thirds had moderate AD (MMSE&gt;=10 AND  &gt;=19),  AND  10%  had  mild  AD  (MMSE&gt;19).  Approximately  two-thirds  of  these  patients  were women  and  had  a  mean  age  at  inclusion  of  75 years.  The  vast  majority  (more  than  90%)  were Caucasian.  The  prevalence  of  concomitant  diseases  and  coadministered  medication  were  similar

<div style=\"page-break-after: always\"></div>

between  patients  in  memantine/donepezil  versus  those  treated  with  placebo/donepezil.  No  relevant differences were observed between both groups of patients.

In pool 1, the exposures to donepezil accrued prior to study start were in the memantine/donepezil (MEM/DPZ) and placebo/donepezil (PBO/DPZ) groups: 1066 and 1071 patient years, respectively. The mean duration of donepezil treatment prior to study start was approximately 2 years and 3 months in both treatment groups.

Further  details  on  duration  of  exposure  by  intervals  are  provided  in  Tables  19-21  for  double  blind placebo controlled studies, pools 1 and 2 and the study 10112, respectively.

Table 19

## Table 20

Table3 DurationofExposuretoIMIPbyIntervals(APTS,DPZ):12-week,DB,PBO-controlledStudies

|                 | PBO/DPZ   | MEM/DPZ   | Total    |
|-----------------|-----------|-----------|----------|
| PatientsTreated | 53        | 61        | 114      |
| 4 weeks n (%)   | 1.9)      | 0 0.0)    | 0.9)     |
| 5.12weeks n (%) | 35 66.0)  | 39 63.9)  | 74 64.9) |
| 13.16weeks n(%） | 17 32.1)  | 22 36.1)  | 39 34.2) |

## Table 21

Table2 DurationofExposuretoIMPbyIntervals(APTS,DPZ):24-week,DB,PBO-controlledStudies

|                 |       | PBO/DPZ   |           | MEM/DPZ         |       | Total     |
|-----------------|-------|-----------|-----------|-----------------|-------|-----------|
| PatientsTreated |       | 465       |           | 473             |       | 938       |
| 1 week          | n (%) | 3         | 0.6)      | 0.2)            | 4     | 0.4) 3.6) |
| 4weeks          | n (%) | 18 43     | 3.9) 9.2) | 16 3.4) 28 5.9) | 34 71 | 7.6)      |
| 5 ：12weeks      | n (%) |           | 2.6)      | 4               | 16    | 1.7)      |
| 13 16weeks      | n (%) | 12        |           | 0.8)            |       |           |
| 17 24weeks      | n (%) | 367       | 78.9)     | 397 83.9)       | 764   | 81.4)     |
| 25-36weeks      | n (%) | 22        | 4.7)      | 27 5.7)         | 49    | 5.2)      |

Table 4 DurationofExposuretoIMIPbyIntervals(APTS,DPZ):52-week,DB,PBO-controlledStudy 10112

|                      | PBO/DPZ   | MEM/DPZ   | Total    |
|----------------------|-----------|-----------|----------|
| PatientsTreated      | 65        | 57        | 122      |
| 4weeks n (%) (%)     | 1.5)      | 1.8)      | 293 1.6) |
| 5 12weeks n          | 52 7.7)   | 41 7.0)   | 7.4)     |
| 13.16weeks n (%) (%) | 3.1)      | 1.8)      | 2.5)     |
| 17 24weeks n         | 1 1.5)    | 3 5.3)    | 4 3.3)   |
| 37 -52 weeks n (%)   | 37 56.9)  | 37 64.9)  | 74 60.7) |
| >1year n (%)         | 19 29.2)  | 11 19.3)  | 30 24.6) |

Note: IMP: investigational medicinal product; APTS: patients-treated Set or Safety Population comprised all patients who took at least one dose of investigational medicinal product ; APTS, DPZ: subset of patients from the APTS or Safety Population who received donepezil concomitantly with memantine or placebo.

Figures for the total number of patients were: 473 (pool 1), 61 (pool 2) and 57 (study 11012) for the group  receiving  MEM/DPZ  and  465  (pool  1),  53  (pool  2)  and  65  (study  11012).  In  the  extension studies, a total of 675 patients received MEM/DPZ in pool 3 and 365 patients in pool 4.

## 2.6.2. Adverse events

Data are presented in Tables 22 and 23 for pools 1, 2 and study 10112. Data for extension studies are presented in Table 24 (pools 3 and 4 and study MEM-MD-03D).

<div style=\"page-break-after: always\"></div>

Table 22

Panel 6 Adverse Events With an Incidence of 5% or More (APTS, DPZ): 12- and 24week, Placebo-controlled Studies Pools

|                                   | 24-week,Placebo-controllerdl Studies Pool   | 24-week,Placebo-controllerdl Studies Pool   | 24-week,Placebo-controllerdl Studies Pool   | 24-week,Placebo-controllerdl Studies Pool   | 12-week,Placebo-controlled Studies Pool   | 12-week,Placebo-controlled Studies Pool   | 12-week,Placebo-controlled Studies Pool   | 12-week,Placebo-controlled Studies Pool   |
|-----------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Preferred Term                    | PBO/DPZ                                     | PBO/DPZ                                     | MEM/DPZ                                     | MEM/DPZ                                     | PBO/DPZ                                   | PBO/DPZ                                   | MEM/DPZ                                   | MEM/DPZ                                   |
|                                   | n                                           | (%)                                         | n                                           | (%)                                         | n                                         | (%)                                       | n                                         | (%)                                       |
| Patients Treated                  | 465                                         |                                             | 473                                         |                                             | 53                                        |                                           | 61                                        |                                           |
| Patients with Adverse Events      | 359                                         | (77.2)                                      | 369                                         | (78.0)                                      | 27                                        | (50.9)                                    | 36                                        | (59.0)                                    |
| Agitation                         | 41                                          | (8.8)                                       | 40                                          | (8.5)                                       | 1                                         | (1.9)                                     | 2                                         | (3.3)                                     |
| Fall                              | 41                                          | (8.8)                                       | 38                                          | (8.0)                                       | 3                                         | (5.7)                                     | 2                                         | (3.3)                                     |
| Confusional state                 | 12                                          | (2.6)                                       | 29                                          | (6.1)**                                     | 0                                         |                                           | 3                                         | (4.9)                                     |
| Dizziness                         | 31                                          | (6.7)                                       | 28                                          | (5.9)                                       | 0                                         |                                           | 2                                         | (3.3)                                     |
| Diarrhoea                         | 37                                          | (8.0)                                       | 26                                          | (5.5)                                       | 5                                         | (9.4)                                     | 4                                         | (6.6)                                     |
| Headache                          | 17                                          | (3.7)                                       | 26                                          | (5.5)                                       | 0                                         |                                           | 0                                         |                                           |
| Upper respiratory tract infection | 22                                          | (4.7)                                       | 24                                          | (5.1)                                       | 1                                         | (1.9)                                     | 1                                         | (1.6)                                     |
| Urinary tract infection           | 31                                          | (6.7)                                       | 21                                          | (4.4)                                       | 2                                         | (3.8)                                     | 2                                         | (3.3)                                     |

PBO: placebo; DPZ: donepezil; MEM: memantine

Cross-reference:

Tables 55 and 61, Module 2.7.4, Summary of Clinical Safety

**p&lt;0.01

Table 23    Adverse Events With an Incidence of 5% or More (APTS, DPZ): study 10112

|                                           | PBO/DPZ   | PBO/DPZ   | MEM/DPZ   | MEM/DPZ   |           |
|-------------------------------------------|-----------|-----------|-----------|-----------|-----------|
| Preferred Term                            | n         | (%)       | n         | (%)       | p-value # |
| Patients Treated                          | 65        |           | 57        |           |           |
| Patients with Adverse Events              | 42        | (64.6)    | 35        | (61.4)    |           |
| Fall                                      | 6         | (9.2)     | 7         | (12.3)    | 0.770     |
| Headache                                  | 3         | (4.6)     | 6         | (10.5)    | 0.302     |
| Confusional state                         | 1         | (1.5)     | 5         | (8.8)     | 0.097     |
| Agitation                                 | 0         | (0.0)     | 4         | (7.0)     | 0.045     |
| Dizziness                                 | 2         | (3.1)     | 4         | (7.0)     | 0.416     |
| Hypertension                              | 0         | (0.0)     | 4         | (7.0)     | 0.045     |
| Oedema peripheral                         | 0         | (0.0)     | 4         | (7.0)     | 0.045     |
| Prostatic specific antigen increased {gs} | 0         | (0.0)     | 1         | (5.6)     | 0.467     |
| Abdominal pain                            | 0         | (0.0)     | 3         | (5.3)     | 0.099     |
| Anxiety                                   | 2         | (3.1)     | 3         | (5.3)     | 0.664     |
| Cough                                     | 2         | (3.1)     | 3         | (5.3)     | 0.664     |
| Depression                                | 0         | (0.0)     | 3         | (5.3)     | 0.099     |
| Diarrhoea                                 | 8         | (12.3)    | 3         | (5.3)     | 0.216     |
| Nasopharyngitis                           | 1         | (1.5)     | 3         | (5.3)     | 0.339     |
| Somnolence                                | 1         | (1.5)     | 3         | (5.3)     | 0.339     |
| Urinary tract infection                   | 4         | (6.2)     | 3         | (5.3)     | 1.000     |
| Weight increased                          | 1         | (1.5)     | 3         | (5.3)     | 0.339     |
| Urinary incontinence                      | 5         | (7.7)     | 2         | (3.5)     | 0.447     |
| Vomiting                                  | 4         | (6.2)     | 2         | (3.5)     | 0.684     |
| Weight decreased                          | 5         | (7.7)     | 1         | (1.8)     | 0.213     |
| Benign prostatic                          | 2         | (6.7)     | 0         | (0.0)     | 0.498     |

hyperplasia {gs}

Coding is done in MedDRA version 13.1

# Fisher^s Exact Test,2-tailed

=p0.05 = pc0.01 =p&lt;0.001

Fina1 Comb0 ST\\_AESG\\_DB\\_RT10112\\_I\\_5P12APR2011:17:18:47 1001/001-TFL/SAD

Build Numbers

Cross-reference:Table 65, Module 2.7.4, Summary of Clinical Sqfety

<div style=\"page-break-after: always\"></div>

## Table 24

Panel8 Adverse Events With an Incidence of 5% or More (APTS, DPZ): Open-label Extension Studies

|                              | 24-28-week,OLEXStudiesPool   | 24-28-week,OLEXStudiesPool   | 24-28-week,OLEXStudiesPool   | 24-28-week,OLEXStudiesPool   | 52-week,OLEX2 StudiesPool   | 52-week,OLEX2 StudiesPool   | 54-week,OLEX StudyMEM- MD-03D   | 54-week,OLEX StudyMEM- MD-03D   |
|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-----------------------------|-----------------------------|---------------------------------|---------------------------------|
| PreferredTerm                | PBO/DPZa                     | PBO/DPZa                     | MEMDPZa                      | MEMDPZa                      | MEM/DPZ                     | MEM/DPZ                     | MEMDPZ                          | MEMDPZ                          |
|                              | n                            | (%)                          | n                            | (%)                          | n                           | (%)                         | n                               | (%)                             |
| Patients Treated             | 324                          |                              | 351                          |                              | 365                         |                             | 119                             |                                 |
| Patients with Adverse Events | 227                          | (70.1)                       | 253                          | (72.1)                       | 266                         | (72.9)                      | 92                              | (77.3)                          |
| Agitation                    | 23                           | (7.1)                        | 27                           | (7.7)                        | 41                          | (11.2)                      | 14                              | (11.8)                          |
| Fall                         | 26                           | (8.0)                        | 23                           | (6.6)                        | 38                          | (10.4)                      | 11                              | (9.2)                           |
| Urinary tract infection      | 25                           | (7.7)                        | 16                           | (4.6)                        | 24                          | (6.6)                       | 14                              | (11.8)                          |
| Dizziness                    | 21                           | (6.5)                        | 18                           | (5.1)                        | 12                          | (3.3)                       | 0                               |                                 |
| Dementia Alzheimer's type    | 1                            | (0.3)                        | 5                            | (1.4)                        | 6                           | (1.6)                       | 7                               | (5.9)                           |
| Prostatomegaly (gs)          | 0                            |                              | 2                            | (1.4)                        | 2                           | (1.4)                       | 2                               | (5.9)                           |
| Pneumonia                    | 5                            | (1.5)                        | 3                            | (0.9)                        | 16                          | (4.4)                       | 6                               | (5.0)                           |

PBO:placebo;DPZ:donepezil;MEM: I:memantine;gs:gender specific Cross-reference:Tables70,78,and 82,Module 2.7.4,Summary ofClinical Safety

a Lead-in treatment group

## 2.6.3. Serious adverse event/deaths/other significant events

## Serious adverse events (SAE)

In  pool  1,  the  incidence  of  SAEs  was  12%  in  the  MEM/DPZ  group  and  11%  in  the  PBO/DPZ  group. During long-term treatment, there was a tendency that incidence of SAEs increased with the study duration: 13%, 22% and 35% respectively in pools 3 (24-28 weeks), 4 (52 weeks) and in 54 week study MEM-MD-03D.

In  pool  1,  SAEs  that  occurred  with  an  incidence  of  1%  or  more  in  either  treatment  group  were  fall (MEM/DPZ: 1%, n=7, 2 rib fracture; PBO/DPZ: 1%, n=6, 3 hip fracture]), hip fracture (MEM/DPZ: 1% [n=3]; PBO/DPZ: 1% [n=5]) ; agitation (MEM/DPZ: 1%, n=7 ; PBO/DPZ: &lt;1%, n=2).  In pool 2, fall was  reported  as  SAEs  in  more  than  1  patient  in  either  treatment  group  (MEM/DPZ:  2%,  n=1; PBO/DPZ: 4%, n=2) as well as ankle fracture (MEM/DPZ: none; PBO/DPZ: 4% , n=2).

In the extension studies, additional types of SAEs occurred with an incidence of 1% or more  and were as follows: syncope (MEM/DPZ: 1%, n=2 ; PBO/DPZ: 1%, n=4),  dehydration (MEM/DPZ: &lt;1%, n=1; PBO/DPZ: 1%, n=4), prostate cancer (MEM/DPZ: none; PBO/DPZ: 2%, n=2), dementia Alzheimer's type (4%, n=5). Pneumonia was reported as SAEs occurring in 10 or more patients (3%) in pool 4 ; dementia Alzheimer's type (4%, n=5), agitation (3%, n=4) and urinary tract infection (3%, n=4) were reported as SAEs occurring in 4 or more patients in study MEM-MD-03D.

## Deaths

A total of 80 patients died during treatment with MEM/DPZ or PBO/DPZ or within 30 days thereafter.

In  pool  1,  a  total  of  8 patients  died  during  treatment  with  MEM/DPZ  (n=3)  or  PBO/DPZ  (n=5).  All events  except  the  cardiac  failure  in  one  patient,  were  considered  not  related  to  treatment  by  the investigator.  In  study  10112,  2  patients  in  the  MEM/DPZ  group  died  during  the  study.  None  of  the events were considered related to treatment by the investigator. None the patients in the PBO/DPZ group died during the study.

<div style=\"page-break-after: always\"></div>

In the extension studies, 58 deaths were reported. In pool 3, a total of 17 patients died, 6 patients who  had  received  MEM/DPZ  and  11  patients  who  had  received  PBO/DPZ  in  the  lead-in  studies.  All events, with the exception of cardiac failure and failure in the PBO/DPZ group, were considered not related to treatment by the investigator.  In pool 4, a total of 19 patients died . All events, with the exception  of  acute  renal  failure  and  1  cerebrovascular  accident,  were  considered  not  related  to treatment by the investigator. In study MEM-MD-03D, a total of 14 patients (12%) died. The events were considered  not  related  to  treatment  by  the  investigator  in  all  patients,  except  in  two  of  them (cardiac arrest and pulmonary embolism cases).

Other deaths were reported in studies MEM-MD-50 (n=2), MEM-MD-54 and MEM-MD-82 (n=10); MEMMD-51  (n=6).  For  3  patients,  the  events  were  considered  related  to  treatment  by  the  investigator (acute  myocardial  infarction,  bundle  branch  block,  and  ventricular  arrhythmia;  cerebrovascular accident; and cardiorespiratory arrest).

## Other significant events

Confusional state, agitation, fall and dizziness related events were considered as significant events and were further analysed. In this analysis, a statistical difference between the two treatment groups in the overall  incidence  of  patients  with  confusional  state  was  noted  (pool  1:  PBO/DZP,  3%,  n=12  versus MEM/DZP,  6%,  n=29,  p≤  0.01).  This  finding  was  considered  driven  mainly  by  differences  in  the titration  period,  indicating  that  confusional  state  may  be  associated  with  memantine  treatment initiation.  In  pool  3  (24-28-week,  open  label  extension  studies),  7  patients  in  each  of  the  lead-in treatment groups reported confusional state during the initial 4- week titration period. The events that occurred during long-term treatment with MEM/DPZ were evenly distributed over time.

## 2.6.4. Laboratory findings

No relevant safety findings were noted in terms of changes in vital signs or laboratory parameters to the exception of liver enzyme elevations, considered as a known risk with memantine treatment.

## 2.6.5. Safety in special populations

No data were initially provided to address the safety in special populations. At the CHMP request, the applicant provided safety subgroup analyses of patients with renal, hepatic impairment, concomitant diseases  (including  cardiovascular  diseases,  hypertension,  diabetes,  or  psychiatric  disorders)  and  of patients treated with selected concomitant medication at baseline.

In patients with renal impairment, a higher incidence of cardiac events was observed in the MEM/DZP group (6 patients, 15%) as compared with the PBO/DZP group which did not experience any cardiac events. In the MEM/DPZ group, 2 patients each experienced cardiac failure congestive and myocardial infarction.  In  addition,  atrial  fibrillation,  bradycardia,  supraventricular  extrasystoles,  supraventricular tachycardia, and tachycardia were reported for one patient each.

In patients with hepatic impairment, 8 of 10 patients in the placebo/donepezil group, compared with only one patient out of 5 in the memantine/donepezil group, experienced adverse events.

No relevant findings were observed across treatment groups in the subgroup analysis of patients with concomitant  diseases.  Higher  incidence  of  vascular  event  was  noted  in  patients  treated  with memantine/donepezil as compared to placebo/donepezil across the different subgroups analysed.

Gastrointestinal events were reported with a higher frequency in patients treated with memantine/donepezil than in patients treated with placebo/donepezil in the subgroup of patients who were  treated  concomitantly  with  anti-inflammatory  anti-rheumatic  agents  and  also  in  the  targeted population (defined as patients with MMSE score 10-19 who are treated with 20 mg memantine/10 mg donepezil or placebo/10 mg donepezil per day).

<div style=\"page-break-after: always\"></div>

The  CHMP  also  noted  the  very  broad  criteria  used  for  defining  patients  with  renal  or  hepatic impairment which  may  hamper  the  comparison  with  the  overall  population  as  the  specificity  of  the analysis become low.

## 2.6.6. Safety related to drug-drug interactions and other interactions

In study MEM-PK-07, there were no serious AEs reported. Twenty (83.3%) of the twenty-four subjects reported a total of 111 treatment emergent adverse events Ninety-eight (98) of the AEs occurred when subjects  were  receiving  donepezil  alone,  3  occurred  following  memantine  alone,  and  10  occurred following  the  co-administration  of  memantine  and  donepezil.  The  events  were  generally  mild  to moderate in severity. The most common AEs were headache, nausea, fatigue, weakness, dizziness, diarrhoea, vomiting, and lightheadedness.

## 2.6.7. Discontinuation due to adverse events

In pool 1, a total of 473 patients received MEM/DPZ and 465 patients received PBO/DPZ. The overall withdrawal rate was 14% in the MEM/DPZ group and 20% the PBO/DPZ group; 7% of the patients in the MEM/DPZ group and 11% of the patients in the PBO/DPZ group withdrew due to adverse events.

In  pool  2,  a  total  of  61  patients  received  MEM/DPZ  and  53  patients  received  PBO/DPZ.  The  overall withdrawal rate was 5% in the MEM/DPZ group and 4% in the PBO/DPZ group; 3% of the patients in the MEM/DPZ group and 2% of the patients in the PBO/DPZ group withdrew due to adverse events. In study 11012, a total of 57 patients received MEM/DPZ and 65 patients received PBO/DPZ. The overall withdrawal rate was 26% in the MEM/DPZ group and 15% in the PBO/DPZ group; 14% of the patients in the MEM/DPZ group and 11% of the patients in the PBO/DPZ group withdrew due to adverse events.

In the extension studies, a total of 675 patients received MEM/DPZ in pool 3 and 365 patients in pool 4. The overall withdrawal rates were respectively 12% and 27%; 4% of the patients withdrew due to adverse  events  in  pool  3  and  10%  in  pool  4.  In  a  54  week  study  (MEM-MD-03D),  a  total  of  119 patients received MEM/DPZ. The overall withdrawal rate was 52%; 15% of the patients withdrew due to adverse events.

## 2.6.8. Post marketing experience

The presented data were mainly based on memantine postmarketing database since the applicant is not marketing donepezil and had therefore no access to the corresponding postmarketing database. The  estimated  cumulative  patient  exposure  to  memantine  in  clinical  studies  and  postmarketing  use was approximately 5.7 million patient years as of 31 December 2010. Up to 15 December 2010, the overall  number  of  memantine  monotherapy  reports  was  2859.  A  total  of  22%  of  the  spontaneous reports received for memantine are from patients who received concomitant donepezil. Overall, both substances  were  assessed  as  suspect  drugs  in  148  cases  (104  serious  and  44  non-serious),  and memantine was assessed as suspect and donepezil as concomitant drug in 701 cases (367 serious and 334 non-serious).

The  most  frequently  (≥2%)  reported  serious  reactions  when  both  drugs  were  assessed  as  suspect: were  fall  (4.7%),  convulsion  (3.8%),  confusional  state  (2.9%),  somnolence  (2.4%),  and  tremor (2.1%).  The  most  frequently  (≥3%)  reported  non-serious  reactions  were  fatigue  (4.3%),  nausea (4.3%), dizziness (4.3%), diarrhoea (3.2%), decreased appetite (3.2%), confusional state (3.2%), and urinary incontinence (3.2%).

The most frequently (≥2%) reported serious reactions when memantine was assessed as suspect and donepezil as concomitant were:  fall (3.7%), convulsion (2.6%), and urinary tract infection (2.0%).

<div style=\"page-break-after: always\"></div>

The most frequently (≥2%) reported non-serious reactions were confusional state (6.6%), agitation (5.3%), dizziness (4.3%), gait disturbance (2.5%), fatigue (2.4%), fall (2.1%), aggression (2.1%).

In an analysis of 2859 spontaneous cases involving memantine as monotherapy, the most frequently reported  events  were  confusional  state  (3.6%),  agitation  (2.9%),  somnolence  (2.7%),  dizziness (2.6%), aggression (2.0%), fall (2.0%), and convulsion (2.0%).

## 2.6.9. Discussion on clinical safety

A total of 1627 patients (in the entire range of AD) have been exposed to memantine in combination with DPZ. The size of the safety database as well as the short (24 weeks) and long term (52 weeks) exposure to the combination were considered sufficient and adequate to characterise the safety profile of the combination (memantine 20 mg/donepezil 10 mg). Safety population was predominantly formed by  Caucasian  females  with  a  median  age  of  75  years  of  age  and  sufficiently  representative  of  the targeted indication. Patient retention in the studies ranged from 95% (12 weeks) to 50% (54 weeks), the withdrawal rates being proportional to the study duration. The number of patients discontinuing due to adverse events did not differ significantly between memantine and placebo groups.

The  most  frequently  reported  AEs  in  the  subjects  receiving  MEM/DPZ  included  agitation,  fall, confusional  state,  dizziness,  diarrhoea,  headache,  upper  respiratory  tract  infection  and  urinary  tract infection. Many of the most common AEs were known to be commonly associated with AD (confusion, agitation,  depression).  Other  AEs  less  likely  to  be  disease  related  were  nausea,  vomiting  and diarrhoea. The majority of AEs was of mild to moderate intensity and did not lead to discontinuation of study medication. The overall incidences of AEs were similar in the MEM/DPZ and PBO/DPZ groups in the short-term exposure, except for confusional state and headache that were more frequent in the combination group. The incidence of most of AEs reported with MEM/DPZ increased with the exposure. Unlike donepezil monotherapy group (in which AEs rates decreased over time), patients treated with the  combined  therapy  showed  significantly  higher  incidence  of  nervous,  digestive  and  urinary  tract disturbances in long term treatment.

Overall, the CHMP considered that the lack of comparison with a treatment group including memantine alone  did  not  allow  to  conclude  on  these  safety  findings  and  that  the  present  safety  analysis  was uncomplete.

A total of 80 patients died during treatment with MEM/DPZ or PBO/DPZ or within 30 days thereafter. In the clinical trials most of deaths were not related to the treatment. In general, mortality rates in both groups  were  similar  and  deaths  related  to  treatment  were  low.  There  were  no  obvious  differences between the groups. Most of serious adverse events were related to cardiovascular, respiratory and infections  disorders  and  did  not  appear  to  show  a  specific  pattern.  Dehydration,  syncope  and pneumonia cases were reported in the studies.

The overall incidence of the serious adverse events was similar between both treatment groups. The majority of SAEs were assessed as unrelated to study medication and SAEs increased with duration of the study. Fall and fractures are the most common SAEs. The incidence of fall (serious or non-serious) was similar between the MEM/DPZ and PBO/DPZ groups in the placebo-controlled studies.

Apart from the elevation of liver enzymes, no relevant findings were noted in terms of changes in vital signs or laboratory parameters. Although, this safety concern is already existing for memantine, it is uncertain  to  what  extent  the  combination  with  donepezil  represents  a  potential  increased  risk  with respect to the monotherapy in the absence of comparison.

Postmarketing data suggested an increased risk of fall, convulsion and tremor for the combination as compared to memantine.

<div style=\"page-break-after: always\"></div>

## Additional analyses

At the CHMP request, the applicant provided additional analyses aiming at comparing the safety profile of the combination versus memantine alone.  These analyses were of qualitative nature and compared safety findings from 4 randomised, double-blind, placebo-controlled studies with memantine monotherapy (MEM-MD-01, MEM-MD-10, MRZ 90001-9605, 99679). MEM-MD-10 and 99679 evaluated the efficacy and safety of memantine in patients with mild to moderate AD, whereas MEM-MD-01 and MRZ 90001-9605 evaluated the efficacy and safety of memantine in patients with moderate to severe AD. Therefore, additional comparisons were made between patients with similar AD severities (mild to moderate or moderate to severe) who have been treated with the memantine/donepezil combination or with memantine monotherapy.

This qualitative comparison did not reveal any new relevant safety findings. The AE profile appeared to be comparable between the combination and memantine group. However, among moderate to severe AD patients, the incidence of confusion and fall in patients with the combination was higher than in patients with memantine monotherapy (confusion : 8% in MEM-MD-02 versus 5% in MEM-MD-01 and 3% in 90001-9605, fall: 7.4% in MEM-MD-02 versus 5.6% in MEM-MD-01 and 7% in 90001-9605).

## 2.6.10. Conclusions on the clinical safety

No  new  relevant  safety  findings  were  noted.  The  CHMP  concluded  that  the  safety  profile  of  the combination (memantine/donepezil) was adequately characterised, considering the AE profiles of the individual components.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The  CHMP  considered  that  the  Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements.

## Risk Management Plan

The applicant submitted a risk management plan.

The CHMP, having considered the data submitted in the application was of the opinion that it was not appropriate to consider risk minimisation activities at this time.

## 2.8. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

Acrescent is a fixed-dose combination (FDC) product of memantine (20 mg) and donepezil (10 mg), presented as film-coated tablets (memantine 20 mg/donepezil 10 mg). Acrescent has been developed as  a  substitution  indication  i.e.  in  patients  adequately  controlled  with  the  individual  products  given concurrently at the same dose level as in the combination, but as separate tablets. This simplification of therapy by decreasing the number of individual dose units to be taken by the patient, may improve patient compliance and was therefore considered as a potential therapeutic advantage to support the present application.

As  a  general  statement,  a  substitution  indication  would  be  acceptable  in  case  of  drugs  with  a  wide therapeutic experience and an adequately established benefit/risk ratio. There are several examples of accepted  fixed  combinations  in  therapeutic  areas  like  diabetes  or  hypertension.  Those  combinations have  demonstrated  to  be  efficacious  and  safe,  improve  patient  adherence  and  they  are  widely recommended in treatment guidelines.

The main evidence presented to document the efficacy of the fixed dose combination came from study MEM-MD-02. This study evaluated the effects of memantine added to ongoing treatment with donepezil in  patients  with  moderate  to  severe  AD.  Subjects  on  donepezil  had  been  treated  for  more  than  6 months before entry into the study at a stable dose (5-10 mg/day). In this study, results showed that patients  on  memantine/donepezil  treatment  achieved  better  scores  in  cognitive  scales  and  in  daily living activities than patients continuing on donepezil at 24 weeks. The two primary endpoints were the mean changes from baseline at week 24 of the SIB total score and the ADCS-ADL modified score and the secondary endpoint included the CIBIC- plus score. At week 24 (LOCF), the mean changes were : 2.5 and  0.9 for SIB  total score and  -3.4 and  2.0 for ADCS-ADL  modified  score  for  the placebo/donepezil  and  memantine/donepezil  groups,  respectively  (SIB  total  score:  p&lt;0.001;  ADCSADL  modified  score:  p=0.028).  For  the  CIBIC-plus  score,  the  mean  value  was  4.66  for  the placebo/donepezil group as compared to 4.41 for the memantine/donepezil group (p=0.027). Results from LOCF and OC analyses were consistent for these endpoints.

## Uncertainty in the knowledge about the beneficial effects.

No specific dose-finding studies have been performed hence the optimum doses for the combination is currently unknown which is a concern in this setting due to continuous need for dose titration in AD patients. The DOMINO study showed that by week 52, 60% of patients had dropped out suggesting that patients did not stay on the highest dose of both memantine/donepezil for a long period, and that a detitration of either component was required.

In  the  presented  clinical  studies,  only  study  MEM-MD-02  had  statistically  positive  results.  However, even  in  this  study,  the  question  on  whether  the  achieved  improvement  is  due  to  the  effect  of memantine could not be determined due to the lack of a control arm including memantine alone. In addition,  study  MEM-MD-02  was  not  specifically  designed  for  the  proposed  fixed-association  dose. Therefore,  the  design  of  this  study  did  not  allow  to  confirm  the  efficacy  of  the  combination  in  the intended population.

<div style=\"page-break-after: always\"></div>

In fact, none of the other studies showed statistical difference on their primary analyses. These studies were also lacking of memantine arm and used different primary endpoints. The majority of them were of small size small size and/or featured a low  proportion of of subjects receiving donepezil.

Additional meta-analyses and non responder analysis performed by the applicant seemed to suggest an additional effect of memantine when compared to donepezil alone. However these results could only be considered as exploratory due to several limitations in their designs (e.g examination of subgroup of patients, post hoc nature of the analyses, different efficacy endpoints assessed in each trial). Of note these analyses were also lacking of a comparison against memantine monotherapy.

The DOMINO study did not show significant benefit in adding memantine to donepezil compared with memantine monotherapy in AD treated patients. After 52 weeks of follow-up there was no significant benefit of adding memantine to donepezil with respect to scores on cognition (MMSE 0.8 points higher with memantine than with placebo; 95% CI, -0.1 to 1.6; p=0.07) or on the activities of daily living (BADLS 0.5 points lower with memantine than with placebo; 95% CI, -2.2 to 1.2; p= 0.57). These data reinforced the uncertainties over the efficacy of the combination and its place in the AD therapy. It also further questioned the use of the proposed fixed combination (memantine 20 mg/donepezil 10 mg)  as  a  substitution  indication  in  the  absence  of  robust  data  demonstrating  the  efficacy  of  the combination in the intended population.

Treatment  guideline/expert  panel  recommendations  on  management  of  AD  vary  across  European Union. Notably, 2 recent European publications ie 'NICE technology appraisal guidance 217: Donepezil, galantamine,  rivastigmine  and  memantine  for  the  treatment  of  Alzheimer's  disease'  and  'EFNS Guidelines for the diagnosis and management of Alzheimer's disease, 2010' stated that the benefits of adding memantine to AChE inhibitors were not clear with the currently available data. Moreover, the conclusions of the NICE review were that 'combination treatment with memantine and AChE inhibitors could not be recommended because of lack of evidence of additional clinical efficacy compared with memantine monotherapy.

Whilst the presented bibliographical analysis had some methodological limitations (e.g. retrospective access to the data, lack of randomization, limited number of countries or patient population involved), they indicate that memantine and AChEIs (mostly donepezil)  are being prescribed as a combination therapy for AD. However their clinical use varies considerably across the EU. The differences could be explained by the limited efficacy of available treatments for the treatment of AD, the lack of consensus in the therapeutic recommendations in force in each country, the differences in the financial supplies of medicines or in the local organization of health systems. These findings also indirectly correlated with the heterogeneity seen among available treatment guidelines/expert panel recommendation.

## Risks

## Unfavourable effects

The  most  frequently  reported  AEs  in  the  subjects  receiving  the  combination  included  agitation,  fall, confusional  state,  dizziness,  diarrhoea,  headache,  upper  respiratory  tract  infection  and  urinary  tract infection. Many of the most common AEs were known to be commonly associated with AD (confusion, agitation,  depression).  Other  AEs  less  likely  to  be  disease  related  were  nausea,  vomiting  and diarrhoea. The majority of AEs was of mild to moderate intensity and did not lead to discontinuation of study medication.

The  overall  incidences  of  AEs  were  similar  in  the  MEM/DPZ  and  PBO/DPZ  groups  in  the  short-term exposure,  except  for  confusional  state  and  headache  that  were  more  frequent  in  the  combination group.  The  incidence  of  most  of  AEs  reported  with  MEM/DPZ  increased  with  the  exposure.  Unlike

<div style=\"page-break-after: always\"></div>

donepezil  monotherapy  group  (in  which  AEs  rates  decreased  over  time),  patients  treated  with  the combined  therapy  showed  significantly  higher  incidence  of  nervous,  digestive  and  urinary  tract disturbances in long term treatment.

Postmarketing data suggested an increased risk of fall, convulsion and tremor for the combination as compared to memantine. On the basis of a qualitative comparison, the overall AE profile appeared to be comparable between the combination and memantine group. However, among moderate to severe AD patients, the incidence of confusion and fall in patients with the combination was higher than in patients with memantine monotherapy.

## Uncertainty in the knowledge about the unfavourable effects

There  were  limited  uncertainties.  The  safety  profile  of  the  combination  (memantine/donepezil)  is adequately characterised, considering the AE profiles of the individual components.

Considering the well characterised AE profiles of the individual components, no new relevant safety findings were noted when memantine and donepezil were concomitantly used.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Whilst  the  simplification  of  therapy  and  as  a  consequence  the  improvement  of  the  compliance  and adherence to therapy are well-recognized benefits of the fixed combinations, this treatment option for AD remains questionable in view of the uncertainties over the efficacy of the combination and its place in AD therapy.

These uncertainties did not support the use of the fixed combination as a substitution indication in the treatment  of  adult  patients  with  moderate  to  moderately  severe  AD  (MMSE  10-19).  Although  it  is acknowledged  that  the  targeted  population  covered  a  group  of  patients  for  which  memantine  and donepezil are currently authorised and the simplification therapy is the intended use, to what extent each active component independently contributes to the efficacy and safety of the combination in the intended population is currently unknown.

The data on simultaneous use of memantine 20 mg and donepezil 10 mg across the European Union are  insufficient  to  support  a  substitution  indication  for  the  fixed  combination  in  the  treatment  of moderate to moderately severe Alzheimer's disease.

## Benefit-risk balance

Having considered the favourable and unfavourable effects of the fixed combination (memantine 20 mg/donepezil 10 mg), the CHMP concluded that the benefit risk balance for Acrescent was negative for the following reasons:

- The  efficacy  of  the  combination  (memantine  20  mg/donepezil  10  mg)  versus  the  components administered individually in the treatment of moderate to moderately severe Alzheimer's disease has not been  sufficiently demonstrated
- The data on simultaneous use of memantine 20 mg and donepezil 10 mg across the European Union are insufficient to support a substitution indication for the fixed combination in the treatment of moderate to moderately severe Alzheimer's disease.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

Based on the CHMP review of data on quality, safety and efficacy for Acrescent in the treatment of moderate to moderately severe Alzheimer's disease who are already on stable daily dose of 20 mg memantine and 10 mg donepezil , the CHMP considers by consensus/majority decision that:

## Whereas

- The  efficacy  of  the  combination  (memantine  20  mg/donepezil  10  mg)  versus  the  components administered individually in the treatment of moderate to moderately severe Alzheimer's disease has not been  sufficiently demonstrated
- The data on simultaneous use of memantine 20 mg and donepezil 10 mg across the European Union are insufficient to support a substitution indication for the fixed combination in the treatment of moderate to moderately severe Alzheimer's disease.

the CHMP is of the opinion that pursuant to Article 12 of Regulation (EC) No 726/2004, the efficacy of the above mentioned medicinal product is not properly or sufficiently demonstrated.

Therefore, the CHMP has recommended the refusal of the granting of the marketing authorisation for Acrescent.